</Abstract>
<AuthorList CompleteYN="Y">
  <Author ValidYN="Y">
    <LastName>Cao</LastName>
    <ForeName>Y-X</ForeName>
    <Initials>YX</Initials>
    <AffiliationInfo>
      <Affiliation>Reproduction Center, Department of Obstetrics, The First Affiliated Hospital, Anhui Medical University, Hefei, China. zzg_100@163.com</Affiliation>
    </AffiliationInfo>
  </Author>
  <Author ValidYN="Y">
    <LastName>Zhang</LastName>
    <ForeName>Z-G</ForeName>
    <Initials>ZG</Initials>
  </Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
        </Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Arch Androl</MedlineTA>
<NlmUniqueID>7806755</NlmUniqueID>
<ISSNLinking>0148-5016</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
  <RegistryNumber>0</RegistryNumber>
  <NameOfSubstance UI="D006063">Chorionic Gonadotropin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
  <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D006063" MajorTopicYN="N">Chorionic Gonadotropin</DescriptorName>
  <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D005307" MajorTopicYN="N">Fertilization in Vitro</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName>
  <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D011256" MajorTopicYN="Y">Pregnancy Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D013087" MajorTopicYN="N">Spermatids</DescriptorName>
  <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
  <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName>
  <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
  <DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName>
  <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
  <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
        </MedlineCitation>
<PubmedData>
<History>
  <PubMedPubDate PubStatus="pubmed">
    <Year>2007</Year>
    <Month>3</Month>
    <Day>17</Day>
    <Hour>9</Hour>
    <Minute>0</Minute>
  </PubMedPubDate>
  <PubMedPubDate PubStatus="medline">
    <Year>2007</Year>
    <Month>5</Month>
    <Day>15</Day>
    <Hour>9</Hour>
    <Minute>0</Minute>
  </PubMedPubDate>
  <PubMedPubDate PubStatus="entrez">
    <Year>2007</Year>
    <Month>3</Month>
    <Day>17</Day>
    <Hour>9</Hour>
    <Minute>0</Minute>
  </PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
  <ArticleId IdType="pubmed">17364455</ArticleId>
  <ArticleId IdType="pii">768865743</ArticleId>
  <ArticleId IdType="doi">10.1080/01485010600889076</ArticleId>
</ArticleIdList>
</PubmedData>
        </PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364457</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Severe hypospadias with micropenis, case of confused sex, psychosocial changes and treatment.</ArticleTitle>
    <Pagination>
      <MedlinePgn>9-12</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Disorders such as severe hypospadias presenting as ambiguous genitalia have serious and potentially life-long consequences for affected individuals and, depending on the underlying cause, are likely to entail surgery in childhood and in later life, psychosocial and psychosexual support, and possible fertility treatment including assisted conception. Genetic males with severe hypospadias who were wrongly brought up as females formed the study group. They were reassigned as males and underwent surgery for correction of hypospadias. Three children with severe hypospadias were reassigned to male gender. Psychosocial changes were made and psychosexual counseling was done. All three have adjusted to their new environment and gender. It is preferable to reassign these children who are genetic males but wrongly assigned as females at birth. Repair of hypospadias, psychosocial changes, and psychosexual counseling will help these children to reorient themselves.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Ravish</LastName>
        <ForeName>I R</ForeName>
        <Initials>IR</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Urology, KLES Kidney Foundation, KLES Hospital, Belgaum, India. irravish@yahoo.com</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Nerli</LastName>
        <ForeName>R B</ForeName>
        <Initials>RB</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kamat</LastName>
        <ForeName>S M</ForeName>
        <Initials>SM</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D002363">Case Reports</PublicationType>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003221" MajorTopicYN="N">Confusion</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003376" MajorTopicYN="N">Counseling</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005783" MajorTopicYN="Y">Gender Identity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007021" MajorTopicYN="N">Hypospadias</DescriptorName>
      <QualifierName UI="Q000469" MajorTopicYN="Y">parasitology</QualifierName>
      <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName>
      <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011606" MajorTopicYN="Y">Psychosexual Development</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364457</ArticleId>
    <ArticleId IdType="pii">768865742</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600889068</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364459</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2015</Year>
    <Month>11</Month>
    <Day>19</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.</ArticleTitle>
    <Pagination>
      <MedlinePgn>17-20</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Patients with lower urinary tract symptoms and enlarged prostate were randomized to receive, in a double blind fashion, either Finasteride 5 mg/day or Dutasteride 0.5 mg/day for a period of 12 weeks. IPSS score, Qmax, and Quality of Life were assessed at the end of 0 and 12 week periods. Dutasteride significantly improved Qmax, reduced IPSS score, and improved Quality of Life as compared to Finasteride at the end of the 12-week period. Dutasteride with its inhibitory effects on type 1 and 2 5alpha-reductase, produces significantly better results than Finasteride.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Ravish</LastName>
        <ForeName>I R</ForeName>
        <Initials>IR</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Urology, KLES Kidney Foundation, Belgaum, India. irravish@yahoo.com</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Nerli</LastName>
        <ForeName>R B</ForeName>
        <Initials>RB</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Amarkhed</LastName>
        <ForeName>S S</ForeName>
        <Initials>SS</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D058891">5-alpha Reductase Inhibitors</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001378">Azasteroids</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>57GNO57U7G</RegistryNumber>
      <NameOfSubstance UI="D018120">Finasteride</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>O0J6XJN02I</RegistryNumber>
      <NameOfSubstance UI="D000068538">Dutasteride</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D058891" MajorTopicYN="Y">5-alpha Reductase Inhibitors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001378" MajorTopicYN="N">Azasteroids</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004231" MajorTopicYN="N">Diuresis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000068538" MajorTopicYN="N">Dutasteride</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018120" MajorTopicYN="N">Finasteride</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName>
      <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014570" MajorTopicYN="N">Urologic Diseases</DescriptorName>
      <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364459</ArticleId>
    <ArticleId IdType="pii">768865740</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600888953</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364456</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Evaluation of sperm chromatin quality and screening of Y chromosome microdeletions in Greek males with severe oligozoospermia.</ArticleTitle>
    <Pagination>
      <MedlinePgn>5-8</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Normal (n = 20) and abnormal (n = 21) semen samples were explored for possible relationships between conventional semen parameters, chromatin status, and microdeletions in the Y chromosome. DNA fragmentation was detected by the terminal deoxynucleotidyl trasferase-mediated dUTP-nick end labelling (TUNEL) assay, chromatin condensation, and DNA packaging quality were assessed by chromomycin A3 (CMA(3)) staining. All men were investigated for Y chromosome microdeletions using polymerase chain reaction (PCR). No deletions were detected in 21 severely oligozoospermic men for the three screened regions (AZFa, AZFb, and AZFc). Men with normal semen parameters showed better chromatin condensation. Spermatozoa with low motility were more likely to contain loosely packaged chromatin. In the abnormal semen group, DNA fragmentation (TUNEL) correlated significantly with sperm motility, concentration, and chromatin packaging assessed by chromomycin A3. However sperm morphology did not correlate significantly with TUNEL and CMA(3) staining.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Mantas</LastName>
        <ForeName>D</ForeName>
        <Initials>D</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Histology and Embryology, Medical School, University of Athens, Greece. drmantas@yahoo.gr</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Angelopoulou</LastName>
        <ForeName>R</ForeName>
        <Initials>R</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Msaouel</LastName>
        <ForeName>P</ForeName>
        <Initials>P</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Plastira</LastName>
        <ForeName>K</ForeName>
        <Initials>K</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>9007-49-2</RegistryNumber>
      <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D053713" MajorTopicYN="N">Azoospermia</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D041322" MajorTopicYN="Y">Chromosomes, Human, Y</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017384" MajorTopicYN="Y">Sequence Deletion</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013076" MajorTopicYN="N">Sperm Count</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013081" MajorTopicYN="N">Sperm Motility</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364456</ArticleId>
    <ArticleId IdType="pii">768865745</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600889159</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364460</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Correlation of seminal parameters with serum lipid profile and sex hormones.</ArticleTitle>
    <Pagination>
      <MedlinePgn>21-3</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The phospholipids and fatty acid composition of sperm are altered under the influence of serum lipids on impaired seminal parameters in infertile men. We studied the correlation of the serum lipid profile and sex hormone results of a group of infertile men with sperm characteristics of 18 infertile men. Semen samples were collected and analyzed. Serum fasted and post-meal glucose levels, insulin, total cholesterol, HDL, LDL, VLDL, triglyceride, FSH, LH, and testosterone measurements were performed. The increased serum VLDL, total triglyceride, and testosterone values were significantly correlated with decreased sperm motility. Serum FSH values were also inversely correlated with normal sperm morphology. The increased VLDL impaired seminal parameters; additionally, increased triglycerides may have deleterious effects on spermatogenesis. Deterioration is related with increased serum VLDL and triglyceride levels.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Ergün</LastName>
        <ForeName>A</ForeName>
        <Initials>A</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Physiology, School of Medicine, Ankara University, Ankara, Turkey. ergun@medicine.ankara.edu.tr</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Köse</LastName>
        <ForeName>S K</ForeName>
        <Initials>SK</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Aydos</LastName>
        <ForeName>K</ForeName>
        <Initials>K</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ata</LastName>
        <ForeName>A</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Avci</LastName>
        <ForeName>A</ForeName>
        <Initials>A</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008079">Lipoproteins, VLDL</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>3XMK78S47O</RegistryNumber>
      <NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>97C5T2UQ7J</RegistryNumber>
      <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
      <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008079" MajorTopicYN="N">Lipoproteins, VLDL</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013076" MajorTopicYN="N">Sperm Count</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013081" MajorTopicYN="N">Sperm Motility</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364460</ArticleId>
    <ArticleId IdType="pii">768865741</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600888961</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364461</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Combination of hypoosmotic swelling/eosin Y test for sperm membrane integrity evaluation: correlations with other sperm parameters to predict ICSI cycles.</ArticleTitle>
    <Pagination>
      <MedlinePgn>25-8</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The objective of our study was to evaluate the accuracy of the combination of hypoosmotic swelling (HOS) and eosin Y (Ey) exclusion tests to predict the ICSI cycles' outcome and its correlations with other sperm parameters. The functional and structural integrity of sperm membrane was evaluated with the combined HOS/Ey test in 95 ICSI cycles and the results were correlated with other sperm parameters, including concentration, motility, strict morphology, and total motile sperm count. The combined HOS/Ey test was evaluated for the prediction of the ICSI cycles' outcome parameters including fertilization, cleavage, and pregnancy rates. The HOS/Ey test presented significant relationships with concentration, motility, and strict morphology (p &lt; 0,0001) but it couldn't predict the fertilization, cleavage, and pregnancy outcomes of ICSI cycles. The combined HOS/Ey test has strong correlations with motility and strict morphology parameters of sperm samples but is not sufficiently sensitive to estimate the outcome of ICSI cycles.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Cincik</LastName>
        <ForeName>M</ForeName>
        <Initials>M</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Obstetrics and Gynecology, Gulhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey. mcincik@yahoo.com</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ergur</LastName>
        <ForeName>A R</ForeName>
        <Initials>AR</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Tutuncu</LastName>
        <ForeName>L</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Muhcu</LastName>
        <ForeName>M</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kilic</LastName>
        <ForeName>M</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Balaban</LastName>
        <ForeName>B</ForeName>
        <Initials>B</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Urman</LastName>
        <ForeName>B</ForeName>
        <Initials>B</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006063">Chorionic Gonadotropin</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
      <QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006063" MajorTopicYN="N">Chorionic Gonadotropin</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D041322" MajorTopicYN="N">Chromosomes, Human, Y</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>
      <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005306" MajorTopicYN="N">Fertilization</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009865" MajorTopicYN="N">Oocytes</DescriptorName>
      <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
      <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010049" MajorTopicYN="N">Ovarian Diseases</DescriptorName>
      <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D020554" MajorTopicYN="N">Sperm Injections, Intracytoplasmic</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName>
      <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
      <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
      <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364461</ArticleId>
    <ArticleId IdType="pii">768865738</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600888912</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364466</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Characterization of poly(ethylene glycol)-modified bovine hemoglobin by capillary zone electrophoresis.</ArticleTitle>
    <Pagination>
      <MedlinePgn>1-10</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>In this study capillary zone electrophoresis (CZE) was used to analyze the poly(ethylene glycol)-modified bovine hemoglobin(PEG-bHb). The results show that CZE separated the subunit of bovine hemoglobin based on the number of PEG conjugating to the protein surface, which makes it possible to evaluate the degree of modification of hemoglobin subunit; meanwhile, it also reflected the stability of PEG attaching to hemoglobin after incubating with hydroxylamine, which makes it successful to detect the distribution of attachment site and evaluate the stability of PEG on the surface of hemoglobin. As a simple, fast and accurate method, CZE is suitable to monitor the production procedures and quality control of the final products of the PEG-bHb.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Li</LastName>
        <ForeName>Xian-Zhong</ForeName>
        <Initials>XZ</Initials>
        <AffiliationInfo>
          <Affiliation>Beijing Kaizheng Biotech Developing Ltd., Beijing, P.R. China.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Yang</LastName>
        <ForeName>Qin-Hong</ForeName>
        <Initials>QH</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Yan</LastName>
        <ForeName>Jiu-Feng</ForeName>
        <Initials>JF</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Xu</LastName>
        <ForeName>Ke</ForeName>
        <Initials>K</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Liu</LastName>
        <ForeName>Jia</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>He</LastName>
        <ForeName>Xue-Ying</ForeName>
        <Initials>XY</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Zhang</LastName>
        <ForeName>Xiao-Wei</ForeName>
        <Initials>XW</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Liu</LastName>
        <ForeName>Qian</ForeName>
        <Initials>Q</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
      <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D019075" MajorTopicYN="N">Electrophoresis, Capillary</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011786" MajorTopicYN="N">Quality Control</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364466</ArticleId>
    <ArticleId IdType="pii">770965360</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974210</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364458</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Relationships between levels of estradiol and testosterone in seminal plasma and GSTM1 polymorphism in infertile men.</ArticleTitle>
    <Pagination>
      <MedlinePgn>13-6</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Glutathione S-transferase M1 (GSTM1) enzyme serves as a steroid-binding protein by its ability to bind to testosterone and estradiol. The levels of total estradiol and testosterone were measured by using an electrochemiluminescence immunoassay in serum and seminal plasma from 103 subjects including 62 subfertile patients. GSTM1 polymorphism was examined using polymerase chain reaction. The estradiol and testosterone levels in seminal plasma were not different in control and subfertile subjects. No role for GSTM1 enzyme as a steroid-binding protein seemed likely as there was also no significant difference in seminal plasma estradiol and testosterone levels according to GSTM1 genotype. Significant positive correlations were found between seminal estradiol and serum estradiol in infertile males, and between seminal testosterone and serum testosterone in fertile males, independent of GSTM1 genotype. GSTM1 polymorphism is not a genetic risk factor of seminal estradiol and testosterone levels in infertile males although further studies are warranted.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Onaran</LastName>
        <ForeName>I</ForeName>
        <Initials>I</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Medical Biology, Istanbul University, Istanbul, Turkey. ilonaran@istanbul.edu.tr</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Aydemir</LastName>
        <ForeName>B</ForeName>
        <Initials>B</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kiziler</LastName>
        <ForeName>A R</ForeName>
        <Initials>AR</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Demiryurek</LastName>
        <ForeName>T</ForeName>
        <Initials>T</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Alici</LastName>
        <ForeName>B</ForeName>
        <Initials>B</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>3XMK78S47O</RegistryNumber>
      <NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>4TI98Z838E</RegistryNumber>
      <NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 2.5.1.18</RegistryNumber>
      <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 2.5.1.18</RegistryNumber>
      <NameOfSubstance UI="C117740">glutathione S-transferase M1</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
      <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005982" MajorTopicYN="N">Glutathione Transferase</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName>
      <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364458</ArticleId>
    <ArticleId IdType="pii">768865744</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600889134</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364462</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Sperm survival: relationship to age-related sperm DNA integrity in infertile men.</ArticleTitle>
    <Pagination>
      <MedlinePgn>29-32</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The purpose of our study was to evaluate the effect of age and sperm DNA integrity on sperm survival. Semen samples from fifty six unselected patients undergoing infertility evaluation were assessed in terms of standard semen parameters, DNA integrity, and sperm survival after 6-24 h of incubation. Prolonged incubation of density gradient selected sperm adversely effects sperm survival in older patients and patients with extensive sperm DNA damage. Immediate preparation of such samples prior to use for assisted reproductive technology (ART) may overcome the negative effect of extended incubation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Moskovtsev</LastName>
        <ForeName>S I</ForeName>
        <Initials>SI</Initials>
        <AffiliationInfo>
          <Affiliation>Andrology Laboratory, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Willis</LastName>
        <ForeName>J</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>White</LastName>
        <ForeName>J</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Mullen</LastName>
        <ForeName>J B M</ForeName>
        <Initials>JB</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>9007-49-2</RegistryNumber>
      <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
      <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013076" MajorTopicYN="N">Sperm Count</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013081" MajorTopicYN="N">Sperm Motility</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName>
      <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
      <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364462</ArticleId>
    <ArticleId IdType="pii">768865746</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600908330</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364467</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Development of zero-link polymers of hemoglobin, which do not extravasate and do not induce pressure increases upon infusion.</ArticleTitle>
    <Pagination>
      <MedlinePgn>11-8</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Intramolecular crosslink of hemoglobin tetramers solved the problem of urine elimination and short intravascular retention time of cell free hemoglobin infusion. It also produced a family of crosslinked hemoglobins with P50 between 18 and 30 mmHg. However, it did not solve the problem of MAP increases in infused animals. It was proven that extravasation of hemoglobin into interstitial fluid was responsible for MAP increases. Extravasation and the MAP increase was avoided using a hemoglobin polymer with average size near 25 MDa. In spite of a very high oxygen affinity, this polymer delivered oxygen to tissues, producing either vasodilation or vasoconstriction according to oxygen needs. It was also proven that cell free hemoglobins are more efficient than red cells in delivering oxygen to tissues.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Bucci</LastName>
        <ForeName>Enrico</ForeName>
        <Initials>E</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Biochemistry and Molecular Biology, University of Maryland Medical School, Baltimore, Maryland, USA. ebucci@umaryland.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kwansa</LastName>
        <ForeName>Herman</ForeName>
        <Initials>H</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Koehler</LastName>
        <ForeName>Raymond C</ForeName>
        <Initials>RC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Matheson</LastName>
        <ForeName>Barbara</ForeName>
        <Initials>B</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>R01 NS038684</GrantID>
        <Acronym>NS</Acronym>
        <Agency>NINDS NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>R01 NS038684-08</GrantID>
        <Acronym>NS</Acronym>
        <Agency>NINDS NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D003432">Cross-Linking Reagents</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C079129">hemoglobin polymer</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
      <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
      <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003432" MajorTopicYN="N">Cross-Linking Reagents</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
      <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364467</ArticleId>
    <ArticleId IdType="pii">770965202</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974277</ArticleId>
    <ArticleId IdType="pmc">PMC2464266</ArticleId>
    <ArticleId IdType="mid">NIHMS48298</ArticleId>
  </ArticleIdList>
  <ReferenceList>
    <Reference>
      <Citation>J Lab Clin Med. 1991 Feb;117(2):115-21</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">1993852</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1600-8</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12816746</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Appl Physiol (1985). 2002 Oct;93(4):1479-86</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12235050</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Crit Care Med. 1996 Apr;24(4):558-65</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8612404</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Lab Clin Med. 2000 Jun;135(6):459-64</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">10850645</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1191-201</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15894576</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Appl Physiol (1985). 2006 Jan;100(1):336-42</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16166237</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Physiol. 1998 Oct;275(4 Pt 2):H1313-21</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9746481</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Physiol Rev. 1994 Jan;74(1):163-219</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8295933</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Lab Clin Med. 1996 Aug;128(2):146-53</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8765210</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Physiol. 1996 Feb;270(2 Pt 2):H466-75</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8779820</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Physiol. 1998 Jun;274(6 Pt 2):H1933-42</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9841479</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Anasthesiol Intensivmed Notfallmed Schmerzther. 2001 Nov;36 Suppl 2:S123-4</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11753718</ArticleId>
      </ArticleIdList>
    </Reference>
  </ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364464</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Increased total antioxidant capacity in seminal plasma of varicocele patients: a multivariate analysis.</ArticleTitle>
    <Pagination>
      <MedlinePgn>37-42</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>To investigate seminal antioxidant systems and their correlation with hormonal pattern in varicocele patients, we studied 33 varicocele (VAR) patients (12 oligozoospermic, 21 normozoospermic) and 34 non-VARs (10 idiopathic oligozoospermic, 24 normozoospermic). Non-enzymatic total antioxidant capacity (TAC) was measured using H(2)O(2)-metamyoglobin, which generates the radical form, spectroscopically detectable, of the chromogen 2,2',-azinobis-3-ethylbenzothiazoline-6-sulphonate (ABTS): time till appearance (Lag) of ABTS*(-) signifies antioxidant concentration. Lag was significantly longer in VARs than controls suggesting ineffective utilization of antioxidants. A significant direct correlation (r = 0.65, p &lt; 0.01) of Lag with sperm count was observed in non-VARs, while in VARs it was inverted, as well as with hematic FSH levels. A multivariate analysis including FSH, Lag, progressive spermatozoa, oligozoospermia and varicocele indicated a strong inverse correlation between FSH and motility (r(2) = 0.31, p &gt; F = 0.0007), not modified by Lag (r(2) = 0.31, p &gt; F = 0.002). Their inverse correlation with Lag may suggest that higher FSH levels, improving sperm antioxidant efficiency, counterbalance varicocele-induced dyspermia.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Mancini</LastName>
        <ForeName>Antonio</ForeName>
        <Initials>A</Initials>
        <AffiliationInfo>
          <Affiliation>Institute of Internal Medicine, Operative Unit of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy. mancini.giac@mclink.it</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Milardi</LastName>
        <ForeName>Domenico</ForeName>
        <Initials>D</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bianchi</LastName>
        <ForeName>Antonio</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Festa</LastName>
        <ForeName>Roberto</ForeName>
        <Initials>R</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Silvestrini</LastName>
        <ForeName>Andrea</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>De Marinis</LastName>
        <ForeName>Laura</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Pontecorvi</LastName>
        <ForeName>Alfredo</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Meucci</LastName>
        <ForeName>Elisabetta</ForeName>
        <Initials>E</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
      <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009845" MajorTopicYN="N">Oligospermia</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013076" MajorTopicYN="N">Sperm Count</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014646" MajorTopicYN="N">Varicocele</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
      <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364464</ArticleId>
    <ArticleId IdType="pii">768862257</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600840756</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364468</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Molecular aspects of the high oxygen affinity of non-hypertensive hexa pegylated hemoglobin, [(SP-PEG5K)(6)-Hb].</ArticleTitle>
    <Pagination>
      <MedlinePgn>19-29</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The development of hexaPEGylated Hb, (SP-PEG5K)(6)-Hb, using the newly designed thiolation-mediated maleimide chemistry based PEGylation, has validated the concept that engineering 'plasma volume expander' -like properties to Hb neutralizes its vasoactivity. The high O(2) affinity of hexaPEGylated Hb has been attributed to the two PEG-5K chains on its two Cys-93(beta) residues. In an attempt to map the influence of the additional four PEG-5K chains of HexaPEGylated Hb on the O(2) affinity, we have now investigated the influence of PEGylation of the surface amino groups alone on the subunit interface interactions and O(2) affinity of Hb using rHb(betaC93A). The molecular radius of PEGylated rHb(betaC93A) was slightly smaller than that of (SP-PEG5K)(6)-Hb, and the overall site-selectivity of PEGylation in the PEGylated rHb(betaC93A) at Lys-residues was comparable to that of (SP-PEG5K)(6)-Hb. Proton NMR studies have shown that the conjugation of the protein with PEG-5K does not have any significant influence on its subunit interface interactions. Surprisingly, the influence of PEGylation on the O(2) affinity and Bohr effect of HbA and rHb(betaC93A) is also nearly the same. Apparently, conjugation of PEG-chains to Lys residues of Hb by the thiolation mediated PEGylation induces unique changes in the structure of the hydration shell of Hb (layer of tightly bound water molecules), which, in turn, induces constraints in its R to T conformational transition to favor the more hydrated R-state.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Li</LastName>
        <ForeName>Dongxia</ForeName>
        <Initials>D</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Physiology, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Manjula</LastName>
        <ForeName>Belur N</ForeName>
        <Initials>BN</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ho</LastName>
        <ForeName>Nancy T</ForeName>
        <Initials>NT</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Simplaceanu</LastName>
        <ForeName>Virgil</ForeName>
        <Initials>V</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ho</LastName>
        <ForeName>Chien</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Acharya</LastName>
        <ForeName>A Seetharama</ForeName>
        <Initials>AS</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>HL58247</GrantID>
        <Acronym>HL</Acronym>
        <Agency>NHLBI NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>HL71064</GrantID>
        <Acronym>HL</Acronym>
        <Agency>NHLBI NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
      <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>059QF0KO0R</RegistryNumber>
      <NameOfSubstance UI="D014867">Water</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
      <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>9034-51-9</RegistryNumber>
      <NameOfSubstance UI="D006441">Hemoglobin A</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>K3Z4F929H6</RegistryNumber>
      <NameOfSubstance UI="D008239">Lysine</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006441" MajorTopicYN="N">Hemoglobin A</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364468</ArticleId>
    <ArticleId IdType="pii">770970752</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974376</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364463</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Testicular sperm retrieval method: histological effects of location of incision.</ArticleTitle>
    <Pagination>
      <MedlinePgn>33-5</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>This research was conducted to evaluate the effects of a transverse vs. longitudinal incision for testicular sperm retrieval. Rats were divided into 4 groups: I: control, II: sham operation, III: longitudinal incision TSRM, IV: transverse incision TSRM. Group II (sham operation) had a dissection of left testis/spermatic cord, then closure of wound. Group III underwent dissection of left testis, then a "longitudinal" incision (15 mm long) of testis, which was fully opened then closed again and sutured with 5-0 Vicryl sutures. Group IV underwent dissection of the left testis, opening of the testis with a "transverse" incision, then closure with 5-0 Vicryl. The seminiferous tubule diameter was 0.118-0.224 mm in all groups. Inflammation and abscess formation occurred in one testis each in the sham and longitudinal incision groups, and in two testes in the transverse incision group. There were no differences in histopathology or scoring between the longitudinal and the transverse incision.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Gümüs</LastName>
        <ForeName>B H</ForeName>
        <Initials>BH</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Urology, Celal Bayar University, Manisa, Turkey. bhgumus@hotmail.com</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Atesçi</LastName>
        <ForeName>Y Z</ForeName>
        <Initials>YZ</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ucer</LastName>
        <ForeName>O</ForeName>
        <Initials>O</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Karatas</LastName>
        <ForeName>T C</ForeName>
        <Initials>TC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Buyuksu</LastName>
        <ForeName>C</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Nese</LastName>
        <ForeName>N</ForeName>
        <Initials>N</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kandiloglu</LastName>
        <ForeName>A R</ForeName>
        <Initials>AR</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000038" MajorTopicYN="N">Abscess</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D053713" MajorTopicYN="N">Azoospermia</DescriptorName>
      <QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012611" MajorTopicYN="N">Scrotum</DescriptorName>
      <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012671" MajorTopicYN="N">Seminiferous Tubules</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D053625" MajorTopicYN="Y">Sperm Retrieval</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
      <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364463</ArticleId>
    <ArticleId IdType="pii">768865739</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600888938</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364469</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Synthesis of a hemoglobin polymer containing antioxidant enzymes using complementary chemistry of maleimides and sulfhydryls.</ArticleTitle>
    <Pagination>
      <MedlinePgn>31-43</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>To increase the overall size of hemoglobin (Hb), we developed a novel system of polymerization based on the complementary chemistry between sulfhydryls and maleimides. The maleimides were introduced onto the protein through N-(-maleimidobutyryloxy) succinimide, while the sulfhydryls were added using 2-iminothiolane hydrochloride (Trauts reagent). Resulting polymers showed SDS-PAGE bands with molecular weights as high as 96 kDa. Size exclusion chromatography has demonstrated species with molecular weight &gt; 700 kDa. The flexibility of the sulfhydryl-maleimide chemistry has also allowed insertion of two antioxidant enzymes, catalase (Cat) and superoxide dismutase (SOD), into the Hb polymer. Cat was incorporated into the heavier fractions of the polymer, while SOD was found throughout the molecular weight range.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Tarasov</LastName>
        <ForeName>Eugene</ForeName>
        <Initials>E</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Chemistry, Loyola University Chicago, Chicago, IL, USA.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Blaszak</LastName>
        <ForeName>Melanie M</ForeName>
        <Initials>MM</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>LaMarre</LastName>
        <ForeName>Jacqueline M</ForeName>
        <Initials>JM</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Olsen</LastName>
        <ForeName>Kenneth W</ForeName>
        <Initials>KW</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008301">Maleimides</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D013438">Sulfhydryl Compounds</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C079129">hemoglobin polymer</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 1.-</RegistryNumber>
      <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 1.11.1.6</RegistryNumber>
      <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 1.15.1.1</RegistryNumber>
      <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002374" MajorTopicYN="N">Catalase</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008301" MajorTopicYN="N">Maleimides</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
      <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013438" MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364469</ArticleId>
    <ArticleId IdType="pii">770971641</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974434</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364470</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Recombinant hemoglobins as artificial oxygen carriers.</ArticleTitle>
    <Pagination>
      <MedlinePgn>45-52</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>This paper describes the approaches we have taken to construct a) mutant hemoglobins with different oxygen affinities, and b) mutant hemoglobins and myoglobins that polymerize to high molecular weight aggregates in an effort to prevent extravasation and the associated vasoactivity. In vivo testing indicates that exchange transfusion of polymeric hemoglobins in mice does not result in vasoactivity and that polymeric hemoglobins are effective oxygen carriers to ischemic tissues irrespective of their oxygen affinity and cooperativity.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Fronticelli</LastName>
        <ForeName>Clara</ForeName>
        <Initials>C</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. cfrontic@jhmi.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Koehler</LastName>
        <ForeName>Raymond C</ForeName>
        <Initials>RC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Brinigar</LastName>
        <ForeName>William S</ForeName>
        <Initials>WS</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>R01 NS038684</GrantID>
        <Acronym>NS</Acronym>
        <Agency>NINDS NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>R01 NS038684-08</GrantID>
        <Acronym>NS</Acronym>
        <Agency>NINDS NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>NS-386684</GrantID>
        <Acronym>NS</Acronym>
        <Agency>NINDS NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D009211">Myoglobin</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005078" MajorTopicYN="N">Exchange Transfusion, Whole Blood</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
      <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009211" MajorTopicYN="N">Myoglobin</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015202" MajorTopicYN="N">Protein Engineering</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364470</ArticleId>
    <ArticleId IdType="pii">770968217</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974467</ArticleId>
    <ArticleId IdType="pmc">PMC2483405</ArticleId>
    <ArticleId IdType="mid">NIHMS48289</ArticleId>
  </ArticleIdList>
  <ReferenceList>
    <Reference>
      <Citation>Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H549-61</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12689854</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Biol Chem. 1998 Sep 11;273(37):23740-9</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9726982</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Crit Care Med. 1996 May;24(5):756-64</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8706450</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Biol Chem. 1995 Dec 22;270(51):30588-92</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8530494</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Nat Biotechnol. 1998 Jul;16(7):672-6</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9661203</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Lab Clin Med. 1995 Nov;126(5):444-51</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">7595029</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Proteins. 2001 Aug 15;44(3):212-22</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11455594</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H908-15</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">10993749</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Appl Physiol (1985). 2002 Oct;93(4):1479-86</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12235050</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Biophys Chem. 2002 Jul 10;98(1-2):115-26</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12128194</ArticleId>
      </ArticleIdList>
    </Reference>
  </ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364465</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0148-5016</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>53</Volume>
        <Issue>1</Issue>
        <PubDate>
          <MedlineDate>2007 Jan-Feb</MedlineDate>
        </PubDate>
      </JournalIssue>
      <Title>Archives of andrology</Title>
      <ISOAbbreviation>Arch Androl</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Varicocele-induced testicular dysfunction may be associated with disruption of blood-testis barrier.</ArticleTitle>
    <Pagination>
      <MedlinePgn>43-8</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The objective of this study was to examine E-cadherin and alpha-catenin expression at the junctions between adjacent Sertoli cells in testicular specimens from patients with varicocele in order to determine the presence of a possible link between blood-testis barrier and pathophysiology of varicocele. A total of 51 testicular biopsies were obtained from 28 infertile men with unilateral or bilateral varicocele. Twenty-three patients had bilateral and 5 had unilateral varicocele, Grade I varicocele was detected in 30 (59%), grade II in 15 (29%) and grade III in 6 (12%) patients. Abnormal expression of E-cadherin and alpha-catenin at the junctions between adjacent Sertoli cells was demonstrated in 100% and 90% of the patients with varicocele, respectively. In those with grade I-III varicocele, the mean E-cadherin and alpha-catenin expression were 7.6 +/- 11.4 and 39 +/- 36; 7.6 +/- 0.0 and 49 +/- 30; 8.3 +/- 9.3 and 58 +/- 33, respectively, but the difference was not significant. Reduced E-cadherin and alpha-catenin expression at the junctions between adjacent Sertoli cells may be associated with disruption of blood-testis barrier in varicocele.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Koksal</LastName>
        <ForeName>I T</ForeName>
        <Initials>IT</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Urology, Akdeniz University, Antalya, Turkey. tkoksal@akdeniz.edu.tr</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ishak</LastName>
        <ForeName>Y</ForeName>
        <Initials>Y</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Usta</LastName>
        <ForeName>M</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Danisman</LastName>
        <ForeName>A</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Guntekin</LastName>
        <ForeName>E</ForeName>
        <Initials>E</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bassorgun</LastName>
        <ForeName>I C</ForeName>
        <Initials>IC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ciftcioglu</LastName>
        <ForeName>A</ForeName>
        <Initials>A</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Arch Androl</MedlineTA>
    <NlmUniqueID>7806755</NlmUniqueID>
    <ISSNLinking>0148-5016</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D051178">alpha Catenin</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001814" MajorTopicYN="N">Blood-Testis Barrier</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012708" MajorTopicYN="N">Sertoli Cells</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013733" MajorTopicYN="N">Testicular Diseases</DescriptorName>
      <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
      <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014646" MajorTopicYN="N">Varicocele</DescriptorName>
      <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051178" MajorTopicYN="N">alpha Catenin</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>15</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364465</ArticleId>
    <ArticleId IdType="pii">768862256</ArticleId>
    <ArticleId IdType="doi">10.1080/01485010600822606</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364471</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Acellular invertebrate hemoglobins as model therapeutic oxygen carriers: unique redox potentials.</ArticleTitle>
    <Pagination>
      <MedlinePgn>53-67</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Natural acellular polymeric hemoglobins (Hb) provide oxygen transport and delivery within many terrestrial and marine invertebrate organisms. It has been our premise that these natural acellular Hbs may serve as models of therapeutic hemoglobin-based oxygen carriers (HBOC). Our attention has focused on the acellular Hb from the terrestrial invertebrate, Lumbricus terrestris (Lt), which possesses a unique hierarchical structure and a unique ability to function extracellularly without oxidative damage. Lumbricus Hb and Arenicola Hb are resistant to autoxidation, chemical oxidation by potassium ferricyanide, and have little or no capacity to transfer electrons to Fe(+3)-complexes at 37 degrees C. An understanding of how these invertebrate acellular oxygen carriers maintain their structural integrity and redox stability in vivo is vital for the design of a safe and effective red cell substitute. We report here a positive redox potential for these giant hemoglobins that may lie at the basis for its resistance to oxidation.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Harrington</LastName>
        <ForeName>John P</ForeName>
        <Initials>JP</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Chemistry, State University of New York, New Paltz, NY 12561, USA. harringj@newpaltz.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kobayashi</LastName>
        <ForeName>Shiho</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Dorman</LastName>
        <ForeName>Scott C</ForeName>
        <Initials>SC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Zito</LastName>
        <ForeName>Samantha L</ForeName>
        <Initials>SL</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hirsch</LastName>
        <ForeName>Rhoda Elison</ForeName>
        <Initials>RE</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C079129">hemoglobin polymer</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004563" MajorTopicYN="N">Electrochemistry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007448" MajorTopicYN="N">Invertebrates</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009835" MajorTopicYN="N">Oligochaeta</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364471</ArticleId>
    <ArticleId IdType="pii">770966046</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974491</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364472</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Trapping hemoglobin in rigid matrices: fine tuning of oxygen binding properties by modulation of encapsulation protocols.</ArticleTitle>
    <Pagination>
      <MedlinePgn>69-79</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Encapsulation of hemoglobin in a biocompatible matrix is a potential strategy for obtaining blood substitutes. Such a system would retain most of the immunogenic and functional properties of the physiologically relevant oxygen carrier but would prevent protein extravasation and dimer/dimer dissociation. We applied this approach by entrapping hemoglobin in wet nanoporous silica gel, in the presence and absence of allosteric effectors. Silica gels, although not suitable for intravenous perfusion, are inert and optically transparent, thus allowing a full characterization of the functional and structural properties of encapsulated hemoglobin by spectroscopic techniques. Results indicate that hemoglobin molecules, entrapped using different protocols, exhibit an oxygen affinity that can be modulated between 12 and 140 torr. This tunability could be exploited to meet distinct clinical needs.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Bruno</LastName>
        <ForeName>Stefano</ForeName>
        <Initials>S</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Biochemistry and Molecular Biology, University of Parma, Parma, Italy.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ronda</LastName>
        <ForeName>Luca</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bettati</LastName>
        <ForeName>Stefano</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Mozzarelli</LastName>
        <ForeName>Andrea</ForeName>
        <Initials>A</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D002214">Capsules</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>60650-90-0</RegistryNumber>
      <NameOfSubstance UI="D058428">Silica Gel</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>7631-86-9</RegistryNumber>
      <NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004337" MajorTopicYN="Y">Drug Carriers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D058428" MajorTopicYN="N">Silica Gel</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012822" MajorTopicYN="N">Silicon Dioxide</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364472</ArticleId>
    <ArticleId IdType="pii">770970014</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974541</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364473</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>One-year observation of Wistar rats after intravenous infusion of hemoglobin-vesicles (artificial oxygen carriers).</ArticleTitle>
    <Pagination>
      <MedlinePgn>81-91</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Hemoglobin-vesicles (HbV) or liposome-encapsulated Hb are artificial oxygen carriers. Our previous studies of the bolus infusion of HbV into Wistar rats showed that HbV was captured by the reticuloendothelial system from the blood stream and degraded completely with no deteriorative effect for 2 weeks. However, one authority on artificial organs research suggested conducting a one-year observation because he experienced, with one lipid-emulsified perfluorocarbon (PFC), that rats died within one year from a pulmonary abnormality after receiving the PFC emulsion due to the unstable dispersion state (personal communication). We thought this would never happen for HbV because the dispersion state of HbV is stable with PEG-modification. To confirm this, we made one-year observations after HbV infusion as suggested. Five male Wistar rats intravenously received 20 ml/kg HbV suspended in saline ([Hb] = 10 g/dL). They were housed in separated cages and provided with food and water ad libitum. All rats survived one year, and were apparently healthy. Their body weights (821+/-75 g) reflected obesity from their confinement in small cages. No histopathological abnormality was found in the lung. Plasma biochemical analyses showed overall normal organ functions. In our previous report, plasma lipid levels increased transiently at 1 or 2 days; then they reverted to the control level at 7 days. One year later, the rats showed much higher plasma lipid levels, a symptom of hyperlipidemia that is attributable to obesity and aging. It seemed the transient increases at the early days had no impact compared with the levels of hyperlipemia of the old rats.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Sakai</LastName>
        <ForeName>Hiromi</ForeName>
        <Initials>H</Initials>
        <AffiliationInfo>
          <Affiliation>Advanced Research Institute for Science and Engineering, Waseda University, Tokyo, Japan.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Tsuchida</LastName>
        <ForeName>Eishun</ForeName>
        <Initials>E</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Horinouchi</LastName>
        <ForeName>Hirohisa</ForeName>
        <Initials>H</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kobayashi</LastName>
        <ForeName>Koichi</ForeName>
        <Initials>K</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D005466">Fluorocarbons</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
      <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005466" MajorTopicYN="N">Fluorocarbons</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
      <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
      <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364473</ArticleId>
    <ArticleId IdType="pii">770969288</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974582</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364474</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Expectations and implications of blood sparing with hemoglobin based oxygen carriers.</ArticleTitle>
    <Pagination>
      <MedlinePgn>93-105</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>To gain insight into the degree to which hemoglobin based oxygen carriers may replace the need for transfusion in surgical patients experiencing blood loss, a simple mathematical model was developed. This model predicts the amount of blood sparing resulting from a bolus infusion of different doses of hemoglobin solution as a function of circulating hemoglobin half-life and degree of erythropoesis enhancement subsequent to treatment. The results of this analysis are consistent with published clinical data and imply that blood sparing increases with increasing oxygen carrier dose and half-life, as well as increasing levels of erythropoesis enhancement. The analysis also predicts that the total circulating hemoglobin content in patients infused with HBOC solutions may reach a minimum value up to ten days after treatment.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Estep</LastName>
        <ForeName>T N</ForeName>
        <Initials>TN</Initials>
        <AffiliationInfo>
          <Affiliation>Chart Biotech Consulting, LLC, Erie, CO 80516, USA. chartbiotech@comcast.net</Affiliation>
        </AffiliationInfo>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName>
      <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004920" MajorTopicYN="N">Erythropoiesis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
      <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
      <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364474</ArticleId>
    <ArticleId IdType="pii">770969329</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974632</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364475</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Thiolation mediated pegylation platform to generate functional universal red blood cells.</ArticleTitle>
    <Pagination>
      <MedlinePgn>107-18</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The PEGylation that adds an extension arm on protein amino groups with the conservation of their positive charge masks the A and D antigens of erythrocytes efficiently. In the present study, the efficiency of masking the antigens of RBC by PEGylation protocols that do not conserve the charge with and without adding extension arms is compared. The conjugation of PEG-5000 to RBCs through the addition of extension arms masked the D antigen more efficiently than the other protocol. A combination of PEG-5 K and PEG-20 K is needed to mask the A antigen, irrespective of the PEGylation approach. The oxygen affinity of the PEGylated RBCs increased by the extension arm facilitated PEGylation. The protocol involving the conjugation of PEG-chains without adding extension arm did not alter the oxygen affinity of RBCs. A combination of PEGylation protocols is an alternate strategy to generate universal red blood cells with good levels of oxygen affinity.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Nacharaju</LastName>
        <ForeName>Parimala</ForeName>
        <Initials>P</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Physiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Manjula</LastName>
        <ForeName>Belur N</ForeName>
        <Initials>BN</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Acharya</LastName>
        <ForeName>Seetharama A</ForeName>
        <Initials>SA</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>HL58247</GrantID>
        <Acronym>HL</Acronym>
        <Agency>NHLBI NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>HL71064</GrantID>
        <Acronym>HL</Acronym>
        <Agency>NHLBI NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
      <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001789">Blood Group Antigens</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D007519">Isoantigens</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D013438">Sulfhydryl Compounds</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
      <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001789" MajorTopicYN="N">Blood Group Antigens</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007519" MajorTopicYN="N">Isoantigens</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D055672" MajorTopicYN="N">Static Electricity</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013438" MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364475</ArticleId>
    <ArticleId IdType="pii">770969941</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974657</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364476</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Long lived microbubbles for oxygen delivery.</ArticleTitle>
    <Pagination>
      <MedlinePgn>119-24</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Exceptionally long lived microbubbles containing a fluorocarbon as part of their filling gas have been obtained by using a fluorinated phospholipid instead of a standard phospholipid as shell component. An unexpected, strong synergistic effect between the fluorocarbon gas and the fluorinated phospholipid has been discovered. Such bubbles could be used for in vivo oxygen delivery, ultrasound contrast imaging and drug delivery.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Gerber</LastName>
        <ForeName>Frédéric</ForeName>
        <Initials>F</Initials>
        <AffiliationInfo>
          <Affiliation>Systèmes Organisés Fluorés à Finalités Thérapeutiques (SOFFT), Institut Charles Sadron, Strasbourg Cedex, France.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Waton</LastName>
        <ForeName>Gilles</ForeName>
        <Initials>G</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Krafft</LastName>
        <ForeName>Marie Pierre</ForeName>
        <Initials>MP</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Vandamme</LastName>
        <ForeName>Thierry F</ForeName>
        <Initials>TF</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D005466">Fluorocarbons</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005466" MajorTopicYN="N">Fluorocarbons</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D045423" MajorTopicYN="Y">Microbubbles</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
      <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364476</ArticleId>
    <ArticleId IdType="pii">771404114</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974939</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364477</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Lyophilized platelets: fifty years in the making.</ArticleTitle>
    <Pagination>
      <MedlinePgn>125-33</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Starting with the work of Klein et al. in the early 1950s, there has been a concerted effort to apply the process of freeze-drying for the preservation of platelets in order to provide hemorrhagic patients with a stable infusible hemostatic agent to stop bleeding. The original attempts did not preserve platelet structural integrity and proved to be of little clinical benefit. However, it was known that fixation by various cross-linking agents rendered platelets able to withstand structurally intact the stresses of lyophilization but with (assumed) complete loss of functionality. Read and coworkers showed that fixed and freeze-dried platelets could respond to ristocetin-induced agglutination, and thus devised a widely accepted assay for von Willebrands factor that demonstrated that reconstituted platelets participated well in this in vitro model of an important interaction in primary hemostasis. This review chronicles the efforts of the authors to refine the fixation process so that the freeze-dried and reconstituted platelets retain fundamental hemostatic properties necessary to stop bleeding. The resultant product has demonstrated correction or reduction of the bleeding times in animal models with platelet deficits including the thrombocytopenic rabbit model of Blajchman and coworkers, a canine cardiopulmonary bypass model of open-heart surgery at East Carolina University (ECU), and a porcine trauma model at The University of North Carolina at Chapel Hill (UNC-CH) involving exsanguination and complete blood exchange with a hemoglobin-based oxygen carrier (HBOC). In addition, it has been shown that the fixation process kills viruses and bacteria spiked into the platelet suspension, indicating that the final material may indeed be the first truly sterile cellular transfusion product. The initial goal for clinical benefit is to prevent exsanguination and hypovolemic shock in combat casualties of armed services personnel, for whom platelet transfusions are most often unavailable. Commercial interests are being brought to bear by Entegrion Inc. (formerly known as Hemocellular Therapeutics Corporation) to transfer this technology to a scaleable manufacturing platform for the production of Stasix, a pharmaceutical preparation of fixed and freeze-dried platelets for intravenous or topical use in the arrest of active hemorrhage in a wide variety of patients with a platelet-related bleeding diathesis. It has taken fifty+ years from the first attempt at making a clinically useful freeze-dried platelet preparation to get to the rapidly-approaching clinical trials of Stasix; stabilization of the platelets has been the key to realizing this advance.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Bode</LastName>
        <ForeName>Arthur P</ForeName>
        <Initials>AP</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Pathology and Laboratory Medicine, East Carolina University, The Brody School of Medicine, Greenville, NC 27858, USA. bodea@ecu.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Fischer</LastName>
        <ForeName>Thomas H</ForeName>
        <Initials>TH</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
      <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001792" MajorTopicYN="Y">Blood Platelets</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001793" MajorTopicYN="N">Blood Preservation</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
      <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005612" MajorTopicYN="N">Freeze Drying</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017713" MajorTopicYN="N">Platelet Transfusion</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016707" MajorTopicYN="N">Tissue Fixation</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
  <NumberOfReferences>22</NumberOfReferences>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364477</ArticleId>
    <ArticleId IdType="pii">770967252</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974962</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364478</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>11</Month>
    <Day>05</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2015</Year>
    <Month>06</Month>
    <Day>03</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1073-1199</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>35</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
        </PubDate>
      </JournalIssue>
      <Title>Artificial cells, blood substitutes, and immobilization biotechnology</Title>
      <ISOAbbreviation>Artif Cells Blood Substit Immobil Biotechnol</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Synthetic oxygen carriers in cardiac tissue engineering.</ArticleTitle>
    <Pagination>
      <MedlinePgn>135-48</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The prominence of cardiovascular diseases has prompted investigations into alternative treatment options, including tissue engineering. Currently, the biggest limitation in cardiac tissue engineering lies in delivering oxygen to all cells within the construct. Synthetic oxygen carriers hold much promise in that they have high affinity for oxygen and can be supplemented to culture medium without adverse effect on the cells. This review highlights two complementary studies by our group that utilized oxygen carriers in cardiac tissue engineering. Experimental and modeling studies were performed to evaluate the effect of a perfluorocarbon (PFC)-based synthetic oxygen carrier, Oxygent, on oxygen supply within tissue engineered cardiac constructs. Porous biorubber scaffolds with an array of parallel channels mimicking the capillary network were seeded with cardiomyocytes and fibroblasts, and cultivated in medium supplemented with PFC. The presence of PFC enhanced the transport of oxygen, increased oxygen concentrations, and yielded constructs that displayed stronger cardiac-like phenotype.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Iyer</LastName>
        <ForeName>Rohin K</ForeName>
        <Initials>RK</Initials>
        <AffiliationInfo>
          <Affiliation>University of Toronto, IBBME, Department of Chemical Engineering and Applied Chemistry, Toronto, Ontario, Canada.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Radisic</LastName>
        <ForeName>Milica</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Cannizzaro</LastName>
        <ForeName>Chris</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Vunjak-Novakovic</LastName>
        <ForeName>Gordana</ForeName>
        <Initials>G</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Artif Cells Blood Substit Immobil Biotechnol</MedlineTA>
    <NlmUniqueID>9431307</NlmUniqueID>
    <ISSNLinking>1073-1199</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001802">Blood Substitutes</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D005466">Fluorocarbons</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>S88TT14065</RegistryNumber>
      <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001802" MajorTopicYN="N">Blood Substitutes</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
      <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005466" MajorTopicYN="N">Fluorocarbons</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
      <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
      <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D023822" MajorTopicYN="N">Tissue Engineering</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
  <NumberOfReferences>12</NumberOfReferences>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>11</Month>
      <Day>6</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364478</ArticleId>
    <ArticleId IdType="pii">770969024</ArticleId>
    <ArticleId IdType="doi">10.1080/10731190600974988</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364480</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>16</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2014</Year>
    <Month>11</Month>
    <Day>20</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1461-6734</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>9</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Attachment &amp; human development</Title>
      <ISOAbbreviation>Attach Hum Dev</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Parents-child role reversal in trilogue play: case studies of trajectories from pregnancy to toddlerhood.</ArticleTitle>
    <Pagination>
      <MedlinePgn>17-31</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Role reversal, whereby a child attempts to meet her parent's adult needs for parenting, intimacy, or companionship, has been identified as a risk factor for developmental disturbances. It has been defined from diverse perspectives as a child attachment strategy, a parent - toddler relational disturbance, and a boundary disturbance between parents and child. The recently discovered infant's triangular capacity, namely the sharing of her attention and affects with both parents, allows one to analyse the infant's contribution to early family dynamics. Role reversal was detected in 4 out of 45 father - mother - infant interactions observed in trilogue play from pregnancy to toddlerhood. The developmental trajectories towards role reversal are explored by means of case analyses. Results are compared with cases of problematic triangulation encountered in the same sample. In role reversal, family interactions are rigidly organized around a "two against one" coalition, whereby the normative hierarchy between parents and child is reversed. The child's triangular capacity is overactivated, controlling the tension between her parents by provocation - animation strategies.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Fivaz-Depeursinge</LastName>
        <ForeName>E</ForeName>
        <Initials>E</Initials>
        <AffiliationInfo>
          <Affiliation>University of Lausanne, Switzerland. Elisabeth.Fivaz@chuv.ch</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Frascarolo</LastName>
        <ForeName>F</ForeName>
        <Initials>F</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Lopes</LastName>
        <ForeName>F</ForeName>
        <Initials>F</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Dimitrova</LastName>
        <ForeName>N</ForeName>
        <Initials>N</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Favez</LastName>
        <ForeName>N</ForeName>
        <Initials>N</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Attach Hum Dev</MedlineTA>
    <NlmUniqueID>100901315</NlmUniqueID>
    <ISSNLinking>1461-6734</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005195" MajorTopicYN="Y">Family Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005219" MajorTopicYN="N">Father-Child Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009034" MajorTopicYN="N">Mother-Child Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010988" MajorTopicYN="N">Play and Playthings</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011582" MajorTopicYN="N">Psychological Theory</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002666" MajorTopicYN="Y">Psychology, Child</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364480</ArticleId>
    <ArticleId IdType="pii">772695727</ArticleId>
    <ArticleId IdType="doi">10.1080/14616730601151425</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364479</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>16</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>11</Month>
    <Day>13</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1461-6734</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>9</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Attachment &amp; human development</Title>
      <ISOAbbreviation>Attach Hum Dev</ISOAbbreviation>
    </Journal>
    <ArticleTitle>A controlled study of Hostile-Helpless states of mind among borderline and dysthymic women.</ArticleTitle>
    <Pagination>
      <MedlinePgn>1-16</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The aim of this study was to determine whether women with borderline personality disorder (BPD) are more likely than those with dysthymia to manifest contradictory Hostile-Helpless (HH) states of mind. A reliable rater blind to diagnosis evaluated features of such mental representations in transcripts of Adult Attachment Interviews from 12 women with BPD and 11 women with dysthymia of similar socioeconomic status (SES), all awaiting psychotherapy. In keeping with three hierarchical (non-independent) a priori predictions regarding the mental representations of women with BPD, the results were that (a) all those with BPD, compared with half the group with dysthymia, displayed HH states of mind; (b) those with BPD manifested a significantly higher frequency of globally devaluing representations; and (c) they exhibited a strong trend toward identifying with the devalued hostile caregiver (58% BPD vs. 18% dysthymic). In addition, significantly more BPD than dysthymic patients made reference to controlling behavior towards attachment figures in childhood. These findings offer fresh insights into the nature of BPD and extend previous evidence concerning affected individuals' patterns of thinking and feeling about childhood attachment figures.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Lyons-Ruth</LastName>
        <ForeName>Karlen</ForeName>
        <Initials>K</Initials>
        <AffiliationInfo>
          <Affiliation>Harvard Medical School, Cambridge, MA, USA. klruth@hms.harvard.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Melnick</LastName>
        <ForeName>Sharon</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Patrick</LastName>
        <ForeName>Matthew</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hobson</LastName>
        <ForeName>R Peter</ForeName>
        <Initials>RP</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>R01 MH062030</GrantID>
        <Acronym>MH</Acronym>
        <Agency>NIMH NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>R01 MH062030-04</GrantID>
        <Acronym>MH</Acronym>
        <Agency>NIMH NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>MH062030</GrantID>
        <Acronym>MH</Acronym>
        <Agency>NIMH NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Attach Hum Dev</MedlineTA>
    <NlmUniqueID>100901315</NlmUniqueID>
    <ISSNLinking>1461-6734</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName>
      <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002649" MajorTopicYN="N">Child Abuse</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName>
      <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006791" MajorTopicYN="Y">Hostility</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009769" MajorTopicYN="Y">Object Attachment</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName>
      <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
      <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364479</ArticleId>
    <ArticleId IdType="pii">772700534</ArticleId>
    <ArticleId IdType="doi">10.1080/14616730601151417</ArticleId>
    <ArticleId IdType="pmc">PMC2585784</ArticleId>
    <ArticleId IdType="mid">NIHMS77886</ArticleId>
  </ArticleIdList>
  <ReferenceList>
    <Reference>
      <Citation>Harv Rev Psychiatry. 2004 Mar-Apr;12(2):94-104</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15204804</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Abnorm Psychol. 1983 Aug;92(3):330-7</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">6619408</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Psychiatry. 1987 Nov;144(11):1426-30</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">3674223</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Clin Psychol. 1988 Jul;44(4):511-6</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">3170755</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Attach Hum Dev. 2003 Dec;5(4):330-52; discussion 409-14</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15061308</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Child Psychol Psychiatry. 2004 Mar;45(3):470-80</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15055367</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Dev Psychopathol. 2003 Fall;15(4):1093-106</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">14984139</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Br J Psychiatry. 2003 Sep;183:239-47</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12948998</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Harv Rev Psychiatry. 2003 Jan-Feb;11(1):8-19</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12866737</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Psychiatr Res. 2003 Mar-Apr;37(2):109-15</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12842164</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Attach Hum Dev. 2003 Mar;5(1):64-77</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12745829</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Neuropsychiatry Clin Neurosci. 2003 Spring;15(2):145-54</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12724454</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Behav Res Ther. 2002 Oct;40(10):1231-40</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12375731</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Nerv Ment Dis. 2002 Jun;190(6):381-7</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12080208</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Dev Psychol. 2001 Nov;37(6):847-62</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11699758</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Harv Rev Psychiatry. 2001 Nov-Dec;9(6):294-301</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11600488</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Pers Disord. 2000 Fall;14(3):264-73</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11019749</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Monogr Soc Res Child Dev. 1999;64(3):67-96; discussion 213-20</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">10597543</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Compr Psychiatry. 1989 Jan-Feb;30(1):18-25</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2924564</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Psychiatry. 1991 May;148(5):648-51</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2018169</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Orthopsychiatry. 1990 Jan;60(1):55-66</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2305845</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Psychiatry. 1989 Apr;146(4):490-5</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2929750</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Psychiatry. 1991 Jul;148(7):864-9</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2053625</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Psychiatry. 1991 Oct;148(10):1378-85</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">1897620</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Abnorm Psychol. 1992 Feb;101(1):61-7</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">1537974</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Compr Psychiatry. 1994 Jul-Aug;35(4):301-5</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">7956187</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Am J Psychiatry. 1997 Aug;154(8):1101-6</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9247396</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Nerv Ment Dis. 2005 Jan;193(1):24-31</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15674131</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Consult Clin Psychol. 1999 Feb;67(1):54-63</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">10028209</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Br J Psychiatry. 1998 Aug;173:172-7</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9850231</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Psychiatry Res. 2005 Apr 15;134(2):169-79</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15840418</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>J Consult Clin Psychol. 1996 Feb;64(1):22-31</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8907081</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Dev Psychopathol. 2005 Spring;17(2):329-47</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16761548</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Dev Psychopathol. 1999 Spring;11(2):225-49</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16506532</ArticleId>
      </ArticleIdList>
    </Reference>
    <Reference>
      <Citation>Dev Psychopathol. 2005 Winter;17(1):1-23</Citation>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15971757</ArticleId>
      </ArticleIdList>
    </Reference>
  </ReferenceList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364481</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>16</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2014</Year>
    <Month>11</Month>
    <Day>20</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1461-6734</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>9</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Attachment &amp; human development</Title>
      <ISOAbbreviation>Attach Hum Dev</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Mother-child attachment in later middle childhood: assessment approaches and associations with mood and emotion regulation.</ArticleTitle>
    <Pagination>
      <MedlinePgn>33-53</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>This study examined the overlap and validity of several measures of mother - child attachment developed for preadolescents. Validity was assessed in part by examining how attachment is related to children's mood and emotion regulation. Mother - child attachment was assessed in a sample of 9 to 11 year-old children using a story stem interview technique and questionnaires. Positive and negative mood were scored from daily logs completed by children. Emotion regulation was assessed with mothers' reports of constructive coping and teacher reports of children's ability to tolerate frustration. Interview and questionnaire measures of attachment were not consistently related to one another, although both were related to mood and emotion regulation. As expected, secure attachment and maternal secure base support were related to higher levels of positive mood, more constructive coping, and better regulation of emotion in the classroom, with effects stronger for emotion regulation than for mood. Children classified Disorganized or Ambivalent displayed the most negative mood. All effects remained significant after controlling for child temperament.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Kerns</LastName>
        <ForeName>Kathryn A</ForeName>
        <Initials>KA</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Psychology, Kent State University, OH 44242, USA. kkerns@kent.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Abraham</LastName>
        <ForeName>Michelle M</ForeName>
        <Initials>MM</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Schlegelmilch</LastName>
        <ForeName>Andrew</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Morgan</LastName>
        <ForeName>Theresa A</ForeName>
        <Initials>TA</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Attach Hum Dev</MedlineTA>
    <NlmUniqueID>100901315</NlmUniqueID>
    <ISSNLinking>1461-6734</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002657" MajorTopicYN="Y">Child Development</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009034" MajorTopicYN="Y">Mother-Child Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009769" MajorTopicYN="Y">Object Attachment</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002666" MajorTopicYN="N">Psychology, Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364481</ArticleId>
    <ArticleId IdType="pii">772696082</ArticleId>
    <ArticleId IdType="doi">10.1080/14616730601151441</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364482</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>16</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2014</Year>
    <Month>11</Month>
    <Day>20</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1461-6734</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>9</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Attachment &amp; human development</Title>
      <ISOAbbreviation>Attach Hum Dev</ISOAbbreviation>
    </Journal>
    <ArticleTitle>God is nowhere, God is now here: attachment activation, security of attachment, and God's perceived closeness among 5-7-year-old children from religious and non-religious homes.</ArticleTitle>
    <Pagination>
      <MedlinePgn>55-71</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>God's perceived closeness (GC) is greater when the attachment system is activated. This conclusion is based primarily on adult studies, but some findings suggest its validity also in childhood. Adult studies have shown GC to vary in relation to security of attachment, but child studies have been few and methodologically limited. In this study, we tested differences between securely and insecurely attached children on GC in attachment activating and neutral conditions, as well as whether parental religiousness acted as a moderator. Participants were forty 5-7-year-olds, from non-religious and Christian homes. The adapted Separation Anxiety Test was used to assess attachment. Participating children were told brief stories about visually represented children in different situations, and placed a God symbol on a felt board to represent GC to the fictional child. Results showed that GC was greater in attachment activating situations, particularly for secure children, supporting a hypothesis of internal working model correspondence between models of Self/Others and God. Although a religious type of home emerged as predictive of GC, no support was found for a moderating role of parental religiousness.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Granqvist</LastName>
        <ForeName>Pehr</ForeName>
        <Initials>P</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Psychology, Uppsala University, Uppsala, Sweden. pehr.granqvist@psyk.uu.se</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ljungdahl</LastName>
        <ForeName>Cecilia</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Dickie</LastName>
        <ForeName>Jane R</ForeName>
        <Initials>JR</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Attach Hum Dev</MedlineTA>
    <NlmUniqueID>100901315</NlmUniqueID>
    <ISSNLinking>1461-6734</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009034" MajorTopicYN="N">Mother-Child Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009769" MajorTopicYN="Y">Object Attachment</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010465" MajorTopicYN="Y">Perception</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002666" MajorTopicYN="Y">Psychology, Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012069" MajorTopicYN="Y">Religion and Psychology</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364482</ArticleId>
    <ArticleId IdType="pii">772696767</ArticleId>
    <ArticleId IdType="doi">10.1080/14616730601151458</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364483</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>05</Month>
    <Day>16</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">1461-6734</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>9</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Attachment &amp; human development</Title>
      <ISOAbbreviation>Attach Hum Dev</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Reliance on leaders and social institutions: an attachment perspective.</ArticleTitle>
    <Pagination>
      <MedlinePgn>73-93</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The ramifications of attachment processes in adulthood at the societal level are explored, specifically, why and under what circumstances followers form attachment relationships with a leader, and how the variability in these relationships can reflect the followers' internal working models of attachment. It is argued that in crisis situations, individuals tend to form affectional bonds with (mostly charismatic) leaders that function in many respects like an attachment relationship between a child and a parent. Relations between individuals and various social institutions, such as community or state, are likewise portrayed as involving attachment dynamics. The provision of security and protection (the safe haven and the secure base functions) by social structures, institutions, and leaders is seen as needed because of the inherent perceived imperfection and fallibility of "regular" attachment figures in adulthood (e.g., parents, friends, and romantic partners). This reliance on leaders and social institutions is seen as reflecting the normative diversification in attachment dynamics that takes place with development. Cultural and individual variations in these processes are also considered.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Mayseless</LastName>
        <ForeName>Ofra</ForeName>
        <Initials>O</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Education, University of Haifa, Haifa, Israel. ofram@construct.haifa.ac.il</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Popper</LastName>
        <ForeName>Micha</ForeName>
        <Initials>M</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Attach Hum Dev</MedlineTA>
    <NlmUniqueID>100901315</NlmUniqueID>
    <ISSNLinking>1461-6734</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D003466" MajorTopicYN="N">Cultural Characteristics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007857" MajorTopicYN="Y">Leadership</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009769" MajorTopicYN="Y">Object Attachment</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016487" MajorTopicYN="N">Parenting</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011582" MajorTopicYN="N">Psychological Theory</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012946" MajorTopicYN="N">Social Welfare</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>5</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364483</ArticleId>
    <ArticleId IdType="pii">772701293</ArticleId>
    <ArticleId IdType="doi">10.1080/14616730601151466</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364484</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Long-term outcomes for individuals who use augmentative and alternative communication: part II--communicative interaction.</ArticleTitle>
    <Pagination>
      <MedlinePgn>1-15</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>This study evaluated the communicative interaction skills of seven young men (ages 19-23 years) who had used AAC systems for at least 15 years. Turn-taking patterns, use of communicative functions, and linguistic complexity were analyzed. Current performance was compared to the participants' skills when they were preschoolers and participated in another study of interaction skills (Light, 1985; Light, Collier, &amp; Parnes, 1985a,b,c). Results indicated that the turn distribution between partners was more equitable than it had been when the participants were preschoolers; five of the participants approached reciprocity in turn taking during at least two of the interactions observed. During interactions with their caregivers, the participants fulfilled most of their obligatory turns and more than half of their non-obligatory turns. The communicative functions used most frequently by the participants were confirmations/denials and provisions of information. Three of the participants demonstrated the ability to use complete and complex syntax and committed few errors in grammar, while the other four participants demonstrated many syntactic errors. The results are discussed with implications for clinical practice and directions for future research.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Lund</LastName>
        <ForeName>Shelley K</ForeName>
        <Initials>SK</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Communication Sciences and Disorders, University of Wisconsin-Milwaukee, Milwaukee, WI 53201, USA. sklund@uwm.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Light</LastName>
        <ForeName>Janice</ForeName>
        <Initials>J</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002547" MajorTopicYN="N">Cerebral Palsy</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
      <QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003143" MajorTopicYN="N">Communication Aids for Disabled</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003144" MajorTopicYN="Y">Communication Barriers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003147" MajorTopicYN="N">Communication Disorders</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005149" MajorTopicYN="N">Facial Expression</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005868" MajorTopicYN="N">Gestures</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008037" MajorTopicYN="N">Linguistics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010379" MajorTopicYN="N">Peer Group</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014743" MajorTopicYN="N">Videotape Recording</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364484</ArticleId>
    <ArticleId IdType="pii">770503840</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610600720442</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364485</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Analysis of spelling error patterns of individuals with complex communication needs and physical impairments.</ArticleTitle>
    <Pagination>
      <MedlinePgn>16-29</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The purpose of this study was to examine the relationships between patterns of spelling error and related linguistic abilities of four persons with complex communication needs and physical impairments, compared to younger individuals without disabilities matched by spelling age. All participants completed a variety of spelling and linguistic tasks to determine overall spelling age, patterns of spelling errors, and abilities across phonemic, orthographic, and morphological awareness. Performance of the spelling-age matched pairs was similar across most of the phonemic, orthographic, and morphological awareness tasks. Analysis of the participants' spelling errors, however, revealed different patterns of spelling errors for three of the spelling-age matched pairs. Within these three pairs, the participants with complex communication needs and physical impairments made most of their spelling errors due to phonemic awareness difficulties, while most of the errors on the part of the participants without disabilities were due to orthographic difficulties. The results of this study lend support to the findings of previous investigations that reported difficulties among individuals with complex communication needs and physical impairments evidence when applying phonemic knowledge to literacy tasks.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Hart</LastName>
        <ForeName>Pamela</ForeName>
        <Initials>P</Initials>
        <AffiliationInfo>
          <Affiliation>Central Missouri State University, Warrensburg, MO 64093, USA. phart@cmsu.edu &lt;phart@cmsu.edu&gt;</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Scherz</LastName>
        <ForeName>Julie</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Apel</LastName>
        <ForeName>Kenn</ForeName>
        <Initials>K</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hodson</LastName>
        <ForeName>Barbara</ForeName>
        <Initials>B</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002547" MajorTopicYN="N">Cerebral Palsy</DescriptorName>
      <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003144" MajorTopicYN="N">Communication Barriers</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003147" MajorTopicYN="N">Communication Disorders</DescriptorName>
      <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004185" MajorTopicYN="Y">Disability Evaluation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008037" MajorTopicYN="N">Linguistics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010700" MajorTopicYN="Y">Phonetics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014825" MajorTopicYN="Y">Vocabulary</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364485</ArticleId>
    <ArticleId IdType="pii">770508531</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610600802737</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364486</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The effect of aided AAC modeling on the expression of multi-symbol messages by preschoolers who use AAC.</ArticleTitle>
    <Pagination>
      <MedlinePgn>30-43</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>A single subject, multiple probe design across participants was used to evaluate the impact of using aided AAC modeling to support multi-symbol message production. Five preschoolers (three who used voice output communication systems, two who used non-electronic communication boards) participated in the study. Aided AAC models were provided by pointing to two symbols on the child's aided AAC system and then providing a grammatically complete spoken model while engaging in play activities. Four of the five preschoolers learned to consistently produce multi-symbol messages; the fifth did not demonstrate consistent gains. The four preschoolers who met criterion all evidenced long-term use of symbol combinations and generalized use of symbol combinations to novel play routines. Results, clinical implications, and future research directions are discussed.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Binger</LastName>
        <ForeName>Cathy</ForeName>
        <Initials>C</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Speech and Hearing Sciences, University of New Mexico, Albuquerque, NM 87131, USA. cbinger@unm.edu</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Light</LastName>
        <ForeName>Janice</ForeName>
        <Initials>J</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <CommentsCorrectionsList>
    <CommentsCorrections RefType="ErratumIn">
      <RefSource>Augment Altern Commun. 2007 Jun;23(2):188-9</RefSource>
    </CommentsCorrections>
  </CommentsCorrectionsList>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001184" MajorTopicYN="N">Articulation Disorders</DescriptorName>
      <QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003143" MajorTopicYN="Y">Communication Aids for Disabled</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002658" MajorTopicYN="N">Developmental Disabilities</DescriptorName>
      <QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010988" MajorTopicYN="N">Play and Playthings</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012660" MajorTopicYN="Y">Semantics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013066" MajorTopicYN="N">Speech-Language Pathology</DescriptorName>
      <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013561" MajorTopicYN="Y">Symbolism</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364486</ArticleId>
    <ArticleId IdType="pii">770523251</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610600807470</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364487</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2020</Year>
    <Month>12</Month>
    <Day>09</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The effect of color on the recognition and use of line drawings by children with severe intellectual disabilities.</ArticleTitle>
    <Pagination>
      <MedlinePgn>44-55</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Line drawings are commonly used as communication symbols for individuals with severe intellectual disabilities. This study investigated the effect of color on the recognition and use of line drawings by young children with severe intellectual disabilities and poor verbal comprehension who were beginning picture users. Drawings where the color of the picture matched the object and where the color of the drawing did not match the object were used, as well as black and white line drawings. Tentative findings suggest that some students with intellectual disabilities may find it more difficult to recognize and line drawings where the color does not match the object compared to line drawings where the color of the drawing does match the color of the object.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Stephenson</LastName>
        <ForeName>Jennifer</ForeName>
        <Initials>J</Initials>
        <AffiliationInfo>
          <Affiliation>Macquarie University Special Education Centre, Macquarie University. NSW, Australia. jennifer.stephenson@speced.sed.mq.edu.au</Affiliation>
        </AffiliationInfo>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003118" MajorTopicYN="Y">Color Perception</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D032882" MajorTopicYN="N">Comprehension</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010364" MajorTopicYN="Y">Pattern Recognition, Visual</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D019989" MajorTopicYN="N">Persons with Mental Disabilities</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
      <QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013067" MajorTopicYN="N">Speech Perception</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013561" MajorTopicYN="N">Symbolism</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364487</ArticleId>
    <ArticleId IdType="pii">770518633</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610600924457</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364488</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>12</Month>
    <Day>03</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The AAC Mentor Project: web-based instruction in sociorelational skills and collaborative problem solving for adults who use augmentative and alternative communication.</ArticleTitle>
    <Pagination>
      <MedlinePgn>56-75</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>In this study, we investigated the effects of a self-paced instructional program, delivered via an accessible website, to teach sociorelational skills and collaborative problem-solving skills to adults with cerebral palsy who used augmentative and alternative communication (AAC). The instruction was designed to prepare participants to serve as mentors, in an Internet-based mentor program, for adolescents and young adults who also used AAC (Light &amp; McNaughton, 2002). The effect of the training program was evaluated in two separate studies utilizing single-subject multiple probe designs: Study 1 investigated the effects of Lesson 1 of the web-based instructional program on the acquisition of sociorelational skills by six adults who used AAC; and, Study 2 focused on the effects of Lesson 2 on the acquisition of collaborative problem-solving skills by 15 adults who used AAC. All participants in Study 1 successfully acquired the target sociorelational skills to help them establish positive mentoring relationships with their protégés, and all participants in Study 2 acquired the collaborative problem-solving skills to support protégés in overcoming challenges in their lives and attaining goals. Results are discussed, along with implications for practice and directions for future research.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Light</LastName>
        <ForeName>Janice</ForeName>
        <Initials>J</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Communication Sciences and Disorders, The Pennsylvania State University, University Park, PA 16802, USA. JCL4@psu.edu &lt;JCL4@psu.edu&gt;</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>McNaughton</LastName>
        <ForeName>David</ForeName>
        <Initials>D</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Krezman</LastName>
        <ForeName>Carole</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Williams</LastName>
        <ForeName>Michael</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Gulens</LastName>
        <ForeName>Maija</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Galskoy</LastName>
        <ForeName>Alix</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Umpleby</LastName>
        <ForeName>Marleah</ForeName>
        <Initials>M</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>H133G8004</GrantID>
        <Agency>PHS HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016430">Clinical Trial</PublicationType>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001184" MajorTopicYN="N">Articulation Disorders</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002547" MajorTopicYN="N">Cerebral Palsy</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003143" MajorTopicYN="Y">Communication Aids for Disabled</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003194" MajorTopicYN="N">Computer-Assisted Instruction</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004519" MajorTopicYN="N">Education, Special</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D020407" MajorTopicYN="Y">Internet</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008611" MajorTopicYN="N">Mentors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364488</ArticleId>
    <ArticleId IdType="pii">770505679</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610600924499</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364489</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2015</Year>
    <Month>11</Month>
    <Day>19</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Brevity and speed of message delivery trade-offs in augmentative and alternative communication.</ArticleTitle>
    <Pagination>
      <MedlinePgn>76-88</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>This study is the third in a series of studies that have concentrated on utterance-based systems--which allow the relatively quick selection of full sentences--and investigated trade-offs faced by users of such systems when there is a pragmatic mismatch between the prestored sentence and the current discourse context. While the previous studies focused on trade-offs between speed of message delivery and either relevance or informativeness, this study investigated the effects of trade-offs between speed of message delivery and brevity on public attitudes. Participating were 96 sales clerks who viewed scripted, videotaped trade-off message conditions in the context of a bookstore interaction and completed a questionnaire designed to assess their attitudes toward customers who used utterance-based systems and his or her communication. Significantly higher mean ratings were found for the trade-off condition involving the quickly delivered message with repetition when compared to each of the slowly delivered, non-repetitive message conditions (i.e., with and without a preceding conversational floorholder). Implications regarding the model of conversational trade-off choices and its technological applications are discussed.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>McCoy</LastName>
        <ForeName>Kathleen F</ForeName>
        <Initials>KF</Initials>
        <AffiliationInfo>
          <Affiliation>University of Delaware, Newark, DE 19716, USA. mccoy@cis.udel.edu &lt;mccoy@cis.udel.edu&gt;</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bedrosian</LastName>
        <ForeName>Jan L</ForeName>
        <Initials>JL</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hoag</LastName>
        <ForeName>Linda A</ForeName>
        <Initials>LA</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Johnson</LastName>
        <ForeName>Dallas E</ForeName>
        <Initials>DE</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>5R01 DC03670-03</GrantID>
        <Acronym>DC</Acronym>
        <Agency>NIDCD NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001290" MajorTopicYN="N">Attitude</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003142" MajorTopicYN="Y">Communication</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003143" MajorTopicYN="N">Communication Aids for Disabled</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006233" MajorTopicYN="N">Disabled Persons</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009790" MajorTopicYN="N">Occupations</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011578" MajorTopicYN="Y">Psycholinguistics</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013060" MajorTopicYN="Y">Speech</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364489</ArticleId>
    <ArticleId IdType="pii">770507477</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610600924515</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364490</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>08</Month>
    <Day>14</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Electronic">1477-3848</ISSN>
      <JournalIssue CitedMedium="Internet">
        <Volume>23</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Augmentative and alternative communication (Baltimore, Md. : 1985)</Title>
      <ISOAbbreviation>Augment Altern Commun</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Research priorities in augmentative and alternative communication as identified by people who use AAC and their facilitators.</ArticleTitle>
    <Pagination>
      <MedlinePgn>89-96</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Two focus groups comprised of adults who used AAC and two focus groups comprised of adult AAC facilitators in Ontario, Canada were asked to identify their own AAC research priorities and to state their levels of agreement with previously identified research priorities in AAC. Members of the focus group who used AAC had physical disabilities since birth except one participant who became disabled at age 2 years. Using focus group methodology and analysis, the participants were asked to generate their own AAC research priorities. A questionnaire and Likert-type scale was used to determine their levels of agreement with six research priorities set a decade earlier by a group of AAC researchers sponsored by the United States-based National Institute of Deafness and other Communication Disorders (NIDCD). Focus group members stressed the importance of (a) preparing people who use AAC to succeed in situations such as maintaining friendships, dating, and finding jobs; (b) improving service delivery of their AAC devices; (c) improving technology in high tech and low tech devices; (d) increasing public awareness of people who use AAC; (e) improving methods of teaching reading skills to people who use AAC; and (f) improving AAC communications training for all healthcare professionals.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>O'Keefe</LastName>
        <ForeName>Bernard M</ForeName>
        <Initials>BM</Initials>
        <AffiliationInfo>
          <Affiliation>University of Toronto, Toronto, Ontario Canada.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kozak</LastName>
        <ForeName>Natalie Bahry</ForeName>
        <Initials>NB</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Schuller</LastName>
        <ForeName>Reinhard</ForeName>
        <Initials>R</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Augment Altern Commun</MedlineTA>
    <NlmUniqueID>8504574</NlmUniqueID>
    <ISSNLinking>0743-4618</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003143" MajorTopicYN="N">Communication Aids for Disabled</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003256" MajorTopicYN="N">Community Participation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006233" MajorTopicYN="N">Disabled Persons</DescriptorName>
      <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017144" MajorTopicYN="Y">Focus Groups</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012106" MajorTopicYN="Y">Research</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>8</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364490</ArticleId>
    <ArticleId IdType="pii">770504058</ArticleId>
    <ArticleId IdType="doi">10.1080/07434610601116517</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364491</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration.</ArticleTitle>
    <Pagination>
      <MedlinePgn>1-8</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Exposure of T cells to inflammatory cytokines leads to phosphorylation-dependent activation of signal transducer and activator of transcription (STAT) 3. T cells from patients with systemic lupus erythematosus (SLE) display increased levels of total and phosphorylated STAT3 which resides primarily in the nucleus. Increased STAT3 is associated with increased expression of target genes. Silencing of STAT3 expression using a small interfering RNA approach resulted in decreased chemokine-provoked SLE T cell migration. Our data suggest that inhibition of STAT3 expression may reverse the signaling aberrations involved in SLE T cell migration.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Harada</LastName>
        <ForeName>Tatsuhiro</ForeName>
        <Initials>T</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kyttaris</LastName>
        <ForeName>Vasileios</ForeName>
        <Initials>V</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Li</LastName>
        <ForeName>Yansong</ForeName>
        <Initials>Y</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Juang</LastName>
        <ForeName>Yuang-Taung</ForeName>
        <Initials>YT</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Wang</LastName>
        <ForeName>Ying</ForeName>
        <Initials>Y</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Tsokos</LastName>
        <ForeName>George C</ForeName>
        <Initials>GC</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D016023">Integrins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016023" MajorTopicYN="N">Integrins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
      <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364491</ArticleId>
    <ArticleId IdType="pii">771299756</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601095148</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364492</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2017</Year>
    <Month>11</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis.</ArticleTitle>
    <Pagination>
      <MedlinePgn>9-15</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The significance of both the acceleratory and inhibitory functions of the CD72 molecule was investigated among patients with systemic lupus erythematosus (SLE) during modification of B cell differentiation. Expression of the CD72 molecule and mRNA on B cells was decreased in SLE with lupus nephritis, while CD100 expression on both CD4+ T cells and CD8+ T cells was not significant in comparison with the controls. When the relationship between CD72 expression and other B cell markers was examined, decreased expression of CD72 was associated with differences in the stage of differentiation. In patients with decreased expression of CD72, switching to IgG was evident, and the disease stage was started to severe. In patients with lupus nephritis, the decreased expression of CD72 was related to class switching on B cells, suggesting that CD72 is a useful marker for determining class switching of B cells in lupus nephritis.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Nakano</LastName>
        <ForeName>Souichiro</ForeName>
        <Initials>S</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Morimoto</LastName>
        <ForeName>Shinji</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Suzuki</LastName>
        <ForeName>Jun</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Mitsuo</LastName>
        <ForeName>Akiko</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Nakiri</LastName>
        <ForeName>Yutaka</ForeName>
        <Initials>Y</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Katagiri</LastName>
        <ForeName>Akira</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Nozawa</LastName>
        <ForeName>Kazuhisa</ForeName>
        <Initials>K</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Amano</LastName>
        <ForeName>Hirofumi</ForeName>
        <Initials>H</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Tokano</LastName>
        <ForeName>Yoshiaki</ForeName>
        <Initials>Y</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hashimoto</LastName>
        <ForeName>Hiroshi</ForeName>
        <Initials>H</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Takasaki</LastName>
        <ForeName>Yoshinari</ForeName>
        <Initials>Y</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D051940">B7-2 Antigen</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C093224">CD100 antigen</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C064228">CD72 protein, human</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C497964">CD86 protein, human</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D039961">Semaphorins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D018127">Tumor Necrosis Factor Receptor Superfamily, Member 7</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 3.2.2.5</RegistryNumber>
      <NameOfSubstance UI="C498154">CD38 protein, human</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 3.2.2.6</RegistryNumber>
      <NameOfSubstance UI="D051997">ADP-ribosyl Cyclase 1</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D051997" MajorTopicYN="N">ADP-ribosyl Cyclase 1</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051940" MajorTopicYN="N">B7-2 Antigen</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017578" MajorTopicYN="N">Immunoglobulin Class Switching</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011947" MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D039961" MajorTopicYN="N">Semaphorins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018127" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 7</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364492</ArticleId>
    <ArticleId IdType="pii">771296722</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601118890</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364493</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis.</ArticleTitle>
    <Pagination>
      <MedlinePgn>16-22</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Understanding the mechanisms that sustain the effects of disease modifying drugs in multiple sclerosis (MS) may help refine current therapies and improve our knowledge of disease pathogenesis. By using cDNA microarrays, we investigated gene expression in the peripheral blood mononuclear cells (PBMC) of 7 MS patients, at baseline (T0) as well as after 1 (T1) and 3 months (T3) of interferon beta-1a (IFN-beta-1a; Rebif 44 microg) therapy. Gene expression changes involved genes of both immunological and non-immunological significance. We validated IL-10 up-regulation, which is in accordance with previous reports, and other novel changes that underscore the capacity of IFN-beta to impair antigen presentation and migration of inflammatory elements into the central nervous system (up-regulation of filamin B and down-regulation of IL-16 and rab7). Overall, gene expression changes became less pronounced after 3 months of therapy, suggesting a homeostatic response to IFN-beta. This may be of use for the design of new treatment schedules.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Annibali</LastName>
        <ForeName>Viviana</ForeName>
        <Initials>V</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Neurology and Center for Experimental Neurological Therapy, S Andrea Hospital, University of Rome La Sapienza, Rome, Italy.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Di Giovanni</LastName>
        <ForeName>Simone</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Cannoni</LastName>
        <ForeName>Stefania</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Giugni</LastName>
        <ForeName>Elisabetta</ForeName>
        <Initials>E</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bomprezzi</LastName>
        <ForeName>Roberto</ForeName>
        <Initials>R</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Mattei</LastName>
        <ForeName>Carlo</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Elkahloun</LastName>
        <ForeName>Abdel</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Coccia</LastName>
        <ForeName>Eliana Marina</ForeName>
        <Initials>EM</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Alfò</LastName>
        <ForeName>Marco</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Orzi</LastName>
        <ForeName>Francesco</ForeName>
        <Initials>F</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ristori</LastName>
        <ForeName>Giovanni</ForeName>
        <Initials>G</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Salvetti</LastName>
        <ForeName>Marco</ForeName>
        <Initials>M</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D003285">Contractile Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D064448">Filamins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D019410">Interleukin-16</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>130068-27-8</RegistryNumber>
      <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>152989-05-4</RegistryNumber>
      <NameOfSubstance UI="C090531">rab7 protein</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>77238-31-4</RegistryNumber>
      <NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 3.6.5.2</RegistryNumber>
      <NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>XRO4566Q4R</RegistryNumber>
      <NameOfSubstance UI="D000068556">Interferon beta-1a</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003285" MajorTopicYN="N">Contractile Proteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D064448" MajorTopicYN="N">Filamins</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000068556" MajorTopicYN="N">Interferon beta-1a</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D019410" MajorTopicYN="N">Interleukin-16</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
      <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364493</ArticleId>
    <ArticleId IdType="pii">771299014</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601135241</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364494</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide.</ArticleTitle>
    <Pagination>
      <MedlinePgn>23-30</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The objective of this study was to determine the expression of transforming growth factor-beta1 messenger RNA (TGF-beta1 mRNA) and the expression of mRNA for TGF-beta receptors (TGF-beta Rs mRNA) in whole peripheral blood of consecutive (treated from several months to several years) systemic lupus erythematosus (SLE) patients (21 women). A further aim of this study was to evaluate the association between expression of the above mentioned parameters in relation to the form of applied therapy (9 patients treated with quinagolide and 12 with quinagolide plus prednisone, azathioprine or cyclosporine A). The control group consisted of 15 healthy women. Most of the patients had mild SLE with SLE disease activity index (SLEDAI) score &lt; 10 at time when blood samples were collected. Laboratory measurements included real-time polymerase chain reaction (RT-QPCR). The expression levels of TGF-beta1 mRNA and mRNA for TGF-beta RII and RIII were significantly lower in patients whereas the expression level of TGF-beta RI was statistically significantly higher in SLE patients than in the controls. A very high positive correlation between TGF-beta1 mRNA expression and expression levels of TGF-beta Rs mRNA was found. In compared subgroups selected according to the form of the applied therapy no statistically significant differences were observed. We conclude that the TGF-beta signaling pathway can be altered in circulating leukocytes derived from treated patients with SLE and that the assumed forms of the applied therapy in the group of patients under consideration are accompanied by similarity in the expression level of transcripts for TGF-beta1 and TGF-beta Rs determined in whole blood. In our investigations, we cannot exclude the influence of the disease itself on the obtained results.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Hrycek</LastName>
        <ForeName>Antoni</ForeName>
        <Initials>A</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Internal, Autoimmune and Metabolic Diseases, Medical University of Silesia, ul Medyków 14, Katowice, Poland. genmar@ka.onet.pl</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kusmierz</LastName>
        <ForeName>Dariusz</ForeName>
        <Initials>D</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Dybała</LastName>
        <ForeName>Tomasz</ForeName>
        <Initials>T</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Swiatkowska</LastName>
        <ForeName>Longina</ForeName>
        <Initials>L</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D000634">Aminoquinolines</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D018125">Receptors, Transforming Growth Factor beta</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>80Q9QWN15M</RegistryNumber>
      <NameOfSubstance UI="C046650">quinagolide</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>83HN0GTJ6D</RegistryNumber>
      <NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>MRK240IY2L</RegistryNumber>
      <NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>VB0R961HZT</RegistryNumber>
      <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000634" MajorTopicYN="N">Aminoquinolines</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
      <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018125" MajorTopicYN="N">Receptors, Transforming Growth Factor beta</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364494</ArticleId>
    <ArticleId IdType="pii">771297515</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601168093</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364495</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2013</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.</ArticleTitle>
    <Pagination>
      <MedlinePgn>31-7</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Th1 and Th2-like cytokines are involved in the pathogenesis of Graves' disease. The shift in balance in IL-12/IL-5 cytokines was applied in judging the immunological events in 74 patients with Graves' disease (50 had ophthalmopathy) during methimazole therapy and in 15 controls. The serum levels of IL-12 and IL-5 were measured with enzyme-linked immunosorbent assay in all Graves' patients. Twelve cases for IL-5 and 20 cases for IL-12 were positive. In Graves' patients only those without ophthalmopathy had higher levels of IL-12 when compared to controls (192.66 +/- 29.19 vs. 85.09 +/- 8.95 pg/ml, P &lt; 0.04). After 2 months of methimazole therapy in Graves' patients without ophthalmopathy an increase in the ratio of IL-12 to IL-5 was also observed as compared to those with eye symptoms (91.78 +/- 34.14 vs. 20.72 +/- 6.36, P &lt; 0.015). Age-related difference in the serum level of IL-5 could be demonstrated between Graves' patients without and those with ophthalmopathy aged &lt; or = 35 years (4.89 +/- 0.57 vs. 50.14 +/- 20.2 pg/ml, P &lt; 0.002). No association was found among the serum levels of IL-5 or IL-12, thyroid hormones and TSH receptor antibodies. The results demonstrated a difference in the balance shift of IL-12/IL-5 between Graves' patients with and without ophthalmopathy. The increased ratio of IL-12 to IL-5 after methimazole therapy could be explained by the elevation of serum IL-12 due to methimazole therapy and the age-related decrease of serum IL-5.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Molnár</LastName>
        <ForeName>Ildikó</ForeName>
        <Initials>I</Initials>
        <AffiliationInfo>
          <Affiliation>3rd Department of Internal Medicine, Kenézy County and Teaching Hospital, Bartók Bu2-26, Debrecen, Hungary. molil@cablenet.hu</Affiliation>
        </AffiliationInfo>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D015848">Interleukin-5</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>187348-17-0</RegistryNumber>
      <NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>554Z48XN5E</RegistryNumber>
      <NameOfSubstance UI="D008713">Methimazole</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006111" MajorTopicYN="N">Graves Disease</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015848" MajorTopicYN="N">Interleukin-5</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008713" MajorTopicYN="N">Methimazole</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
      <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
      <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
      <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364495</ArticleId>
    <ArticleId IdType="pii">771300864</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601165388</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364497</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2019</Year>
    <Month>12</Month>
    <Day>10</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Infection and vaccination in chronic fatigue syndrome: myth or reality?</ArticleTitle>
    <Pagination>
      <MedlinePgn>48-53</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Chronic fatigue syndrome (CFS) is characterized by severe disabling fatigue lasting for more than 6 months associated with physical and mental disturbances such as headache, arthralgia, myalgia, memory impairment, sore throat and tender lymph nodes. The exact pathogenesis is still unknown. Several models were proposed to explain its etiology including chronic infection, endocrine dysfunction, autonomic imbalance, depression, decreased immunity states and an aberrant reaction to infection. No convincing evidence was found to support any of the suggested pathogenic mechanisms. The current concept is that CFS pathogenesis is a multi factorial condition in which an infective agent cause an aberrant immune response characterized by a shift to Th-2 dominant response. When the response fails to be switched-off, a chronic immune activation occurs and clinically expressed as the symptomatology of CFS. Vaccinations are used in order to stimulate the immune system to induce a persistent immunity against the favorable antigens. Several syndromes that contain chronic fatigue as one of their symptoms, such as "Gulf war syndrome" and macrophagic myofasciitis were related to vaccinations. Can vaccinations induce the aberrant immune response of CFS? Little is known about this issue. There are some reports on CFS occurring after vaccination, but few prospective and retrospective studies failed to find such an association. A working group of the Canadian Laboratory Center for Disease Control (LCDC) that was founded in order to examine the suspected association between CFS and vaccinations concluded that there is no evidence that relates CFS to vaccination. Further studies are requested to examine this issue since it is very conceivable that if infection can lead to CFS, vaccination may also lead to it in the same immune-mediated pathogenesis.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Appel</LastName>
        <ForeName>Shmuel</ForeName>
        <Initials>S</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Chapman</LastName>
        <ForeName>Joab</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Shoenfeld</LastName>
        <ForeName>Yehuda</ForeName>
        <Initials>Y</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
      <PublicationType UI="D016454">Review</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D015673" MajorTopicYN="N">Fatigue Syndrome, Chronic</DescriptorName>
      <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
      <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName>
      <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
      <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
  <NumberOfReferences>49</NumberOfReferences>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364497</ArticleId>
    <ArticleId IdType="pii">771296897</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930701197273</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364496</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2016</Year>
    <Month>11</Month>
    <Day>24</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Immunization of nonautoimmune mice with DNA binding domains of the largest subunit of RNA polymerase I results in production of anti-dsDNA and anti-Sm/RNP antibodies.</ArticleTitle>
    <Pagination>
      <MedlinePgn>38-47</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>Antibodies against the N-terminal (NT) but not the basic domain (BD), DNA binding regions of the largest subunit (S1) of RNA polymerase I (RNAPI) were detected in the sera of MRL-lpr/lpr lupus mice. Antibodies against both RNAPI(S1)-NT and -BD, as well as other systemic lupus erythematosus (SLE) autoantigens (La, ribosomal P proteins and Sm/RNP) were produced by rabbits immunized with anti-DNA antibodies that had been affinity purified from SLE patients. Immunization of nonautoimmune mice (Balb/c) with RNAPI(S1)-NT, RNAPI(S1)-BD, or La in the form of GST fusion proteins, induced production of anti-double-stranded (ds) DNA and anti-Sm/RNP. GST-P1 did not induce an anti-dsDNA response in these mice. These results demonstrate that RNAPI(S1)-NT, RNAPI(S1)-BD and La can participate in an anti-autoantigen/anti-DNA antibody loop during an SLE-like autoimmune response.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Sciascia</LastName>
        <ForeName>Sandra A</ForeName>
        <Initials>SA</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Molecular Biosciences, University of Kansas. Lawrence, KS 66045, USA.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Robson</LastName>
        <ForeName>Kristina</ForeName>
        <Initials>K</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Zhu</LastName>
        <ForeName>Liangjin</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Garland</LastName>
        <ForeName>Michael</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Grabosch</LastName>
        <ForeName>Shannon</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Kelamis</LastName>
        <ForeName>Joseph</ForeName>
        <Initials>J</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Messamore</LastName>
        <ForeName>Will</ForeName>
        <Initials>W</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bradley</LastName>
        <ForeName>Todd</ForeName>
        <Initials>T</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Sourk</LastName>
        <ForeName>Allison</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Westberg</LastName>
        <ForeName>Lindsey</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Goodnight</LastName>
        <ForeName>Waco</ForeName>
        <Initials>W</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Tongson</LastName>
        <ForeName>Krystina</ForeName>
        <Initials>K</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Holloway</LastName>
        <ForeName>Naomi</ForeName>
        <Initials>N</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Wardak</LastName>
        <ForeName>Zabi</ForeName>
        <Initials>Z</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Sudyka</LastName>
        <ForeName>Michelle</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Masrani</LastName>
        <ForeName>Shriti</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Chintalapati</LastName>
        <ForeName>Sanket</ForeName>
        <Initials>S</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Cagaanan</LastName>
        <ForeName>Manuel</ForeName>
        <Initials>M</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Brown</LastName>
        <ForeName>John C</ForeName>
        <Initials>JC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Stetler</LastName>
        <ForeName>Dean A</ForeName>
        <Initials>DA</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D017411">Ribonucleoproteins, Small Nuclear</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C035416">SS-B antigen</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D055517">snRNP Core Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 2.7.7.6</RegistryNumber>
      <NameOfSubstance UI="D012318">RNA Polymerase I</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012318" MajorTopicYN="N">RNA Polymerase I</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012261" MajorTopicYN="N">Ribonucleoproteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017411" MajorTopicYN="N">Ribonucleoproteins, Small Nuclear</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D055517" MajorTopicYN="N">snRNP Core Proteins</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364496</ArticleId>
    <ArticleId IdType="pii">771298331</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601185550</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364498</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2012</Year>
    <Month>06</Month>
    <Day>22</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Anti-viral effector T cell responses and trafficking are not dependent upon DRAK2 signaling following viral infection of the central nervous system.</ArticleTitle>
    <Pagination>
      <MedlinePgn>54-65</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>The signaling events involved in T cell trafficking into the central nervous system (CNS) following viral infection are not fully understood. Intracerebral infection of mice with mouse hepatitis virus (MHV) results in an acute encephalomyelitis followed by an immune-mediated demyelinating disease. Although chemokine signaling is critical in promoting T cell infiltration into the CNS and control of viral replication, additional signaling pathways have not been completely explored. DRAK2, a lymphoid-restricted serine/threonine kinase, prevents spurious T cell activation. Yet Drak2- / - mice are resistant to MOG-induced experimental autoimmune encephalomyelitis (EAE), suggesting that DRAK2 may influence T cell trafficking into the CNS. In order to further characterize the molecular mechanisms governing T cell activation and accumulation within the CNS in response to viral infection, MHV was instilled into the CNS of Drak2- / - mice. Drak2-deficient T cells possessed no obvious defects in trafficking into the CNS following MHV infection. Moreover, Drak2-deficient T cell activation, expansion and cytokine production were unimpaired in response to acute MHV infection. These results demonstrate that DRAK2 signaling is dispensable for T cell recruitment into the CNS following viral infection, suggesting that the resistance of Drak2- / - mice to EAE is not due to overt T cell trafficking defects.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Ramos</LastName>
        <ForeName>Stephanie J</ForeName>
        <Initials>SJ</Initials>
        <AffiliationInfo>
          <Affiliation>Center for Immunology and Department of Molecular Biology &amp; Biochemistry, University of California, Irvine, CA, 92697-3900, USA.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hardison</LastName>
        <ForeName>Jenny L</ForeName>
        <Initials>JL</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Stiles</LastName>
        <ForeName>Linda N</ForeName>
        <Initials>LN</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Lane</LastName>
        <ForeName>Thomas E</ForeName>
        <Initials>TE</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Walsh</LastName>
        <ForeName>Craig M</ForeName>
        <Initials>CM</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>AI063419</GrantID>
        <Acronym>AI</Acronym>
        <Agency>NIAID NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>NS041249</GrantID>
        <Acronym>NS</Acronym>
        <Agency>NINDS NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
      <Grant>
        <GrantID>T32 AI060573</GrantID>
        <Acronym>AI</Acronym>
        <Agency>NIAID NIH HHS</Agency>
        <Country>United States</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>EC 2.7.11.1</RegistryNumber>
      <NameOfSubstance UI="C495197">Drak2 protein, mouse</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 2.7.11.1</RegistryNumber>
      <NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004679" MajorTopicYN="N">Encephalomyelitis</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
      <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364498</ArticleId>
    <ArticleId IdType="pii">771297938</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930600996700</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364499</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2018</Year>
    <Month>12</Month>
    <Day>01</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions.</ArticleTitle>
    <Pagination>
      <MedlinePgn>66-72</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the prevalence of mucosal autoantibodies to survivin in patients with human papillomavirus (HPV)-associated cervical cancer and precursor lesions.</AbstractText>
      <AbstractText Label="METHODS" NlmCategory="METHODS">Cervical mucus from 117 HPV-associated cervical cancer, 102 high-grade squamous intraepithelial lesion (HSIL), 107 low-grade SIL (LSIL), and 80 normal controls were tested by ELISA using either full length recombinant survivin or survivin-derived peptides. Survivin expression in cervical tissue biopsies was studied by Western Blotting.</AbstractText>
      <AbstractText Label="RESULTS" NlmCategory="RESULTS">Cervical mucus from 33 cervical cancer (28.2%), 17 HSIL (16.6%), and 8 LSIL (7.4%) patients reacted with recombinant survivin. The IgA-class antibody response was significantly higher than that observed in the normal controls. The level of mucosal anti-survivin response was associated to the level and intensity of survivin expression in the different lesions. Finally, reactivity against a survivin Nt-derived peptide was found more frequently than reactivity against a Ct-derived peptide.</AbstractText>
      <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IgA-class autoantibodies against survivin are present in a substantial proportion of cervical mucus from patients with HPV-associated cervical cancer, and precursor lesions. Mucosal anti-survivin response is positively associated with the level of survivin expression and the grade of cervical lesion.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Jimenez</LastName>
        <ForeName>Lizbeth Gonzalez</ForeName>
        <Initials>LG</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Circuito Escolar s/n, Ciudad Universitaria, Mexico City, CP 04510, Mexico.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Aguilar</LastName>
        <ForeName>Maria Cristina</ForeName>
        <Initials>MC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Monroy</LastName>
        <ForeName>Olga L</ForeName>
        <Initials>OL</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Cruz-Talonia</LastName>
        <ForeName>Fernando</ForeName>
        <Initials>F</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Cruz</LastName>
        <ForeName>Rosa M</ForeName>
        <Initials>RM</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Huitron</LastName>
        <ForeName>Carlos</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Rocha-Zavaleta</LastName>
        <ForeName>Leticia</ForeName>
        <Initials>L</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D016448">Multicenter Study</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C107489">BIRC5 protein, human</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D051034">Inhibitor of Apoptosis Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D000077022">Survivin</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018290" MajorTopicYN="N">Cervical Intraepithelial Neoplasia</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002582" MajorTopicYN="N">Cervix Mucus</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
      <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051034" MajorTopicYN="N">Inhibitor of Apoptosis Proteins</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D027383" MajorTopicYN="N">Papillomaviridae</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>
      <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000077022" MajorTopicYN="N">Survivin</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
      <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
      <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364499</ArticleId>
    <ArticleId IdType="pii">771298174</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601042603</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364500</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>03</Month>
    <Day>16</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>1</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Feb</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Anti-68 kDa antibodies in autoimmune sensorineural hearing loss: are these autoantibodies really a diagnostic tool?</ArticleTitle>
    <Pagination>
      <MedlinePgn>73-8</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Autoimmune sensorineural hearing loss (ASNHL) is a relatively rare disorder which can lead to total deafness. At present, no specific laboratory test with adequate sensitivity and specificity is available to confirm the clinical suspicion of ASNHL. The aim of this study was to identify if evaluation of anti-hsp70 antibodies is an accurate diagnostic tool in patients affected by ASNHL.</AbstractText>
      <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Prospective study.</AbstractText>
      <AbstractText Label="METHODS" NlmCategory="METHODS">During 4-year (2001-2005), all patients with SNHL who were referred to the Eye, Ear, Nose and Throat Department of Parma University, Italy, underwent specific tests to determine the autoimmune origin of the disease. Patients with a consistent suspicion of ASNHL underwent the routine serologic tests and a test for determination of anti-hsp70 antibodies. The same patients were divided into three groups: (1) idiopathic ASNHL; (2) ASNHL associated with ocular inflammation, i.e. Cogan's Syndrome; (3) ASNHL associated with a systemic autoimmune disease (SAD). The control group included: (1) healthy subjects; and (2) patients affected by SAD, without any ocular or audiovestibular disease.</AbstractText>
      <AbstractText Label="RESULTS" NlmCategory="RESULTS">88 subjects (67 patients, defined as "study group", and 21 controls) were evaluated. Anti-hsp70 antibodies were isolated in 52% of the study group patients, and in 4% of the control group (chi2 = 13.009, p &lt; 0.01). In the idiopathic ASNHL patients, 59.5% were found positive for anti-hsp70 antibodies. About 50% of patients affected by CS and 37.5% of patients affected by SAD with SNHL were found positive. In the control group, anti-hsp70 antibodies were found in 8.3% of healthy subjects and in none of the patients with SAD and no hearing loss.</AbstractText>
      <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study confirms the value of the anti-hsp70 test in the serological diagnosis of autoimmune hearing loss. It is still the only available diagnostic marker that identifies an autoimmune origin of hearing loss.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Bonaguri</LastName>
        <ForeName>Chiara</ForeName>
        <Initials>C</Initials>
        <AffiliationInfo>
          <Affiliation>Diagnostic Laboratory Department, Parma Hospital, Parma, Italy.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Orsoni</LastName>
        <ForeName>Jelka G</ForeName>
        <Initials>JG</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Zavota</LastName>
        <ForeName>Laura</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Monica</LastName>
        <ForeName>Cesare</ForeName>
        <Initials>C</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Russo</LastName>
        <ForeName>Annalisa</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Pellistri</LastName>
        <ForeName>Isabella</ForeName>
        <Initials>I</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Rubino</LastName>
        <ForeName>Pierangela</ForeName>
        <Initials>P</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Giovannelli</LastName>
        <ForeName>Luigi</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Manzotti</LastName>
        <ForeName>Francesca</ForeName>
        <Initials>F</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Piazza</LastName>
        <ForeName>Fabio</ForeName>
        <Initials>F</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C081884">heat-shock protein 70.1</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006319" MajorTopicYN="N">Hearing Loss, Sensorineural</DescriptorName>
      <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
      <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>20</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364500</ArticleId>
    <ArticleId IdType="pii">771299674</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601119377</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364501</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>18</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>19</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>2</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Celiac disease associated antibodies in persons with latent autoimmune diabetes of adult and type 2 diabetes.</ArticleTitle>
    <Pagination>
      <MedlinePgn>103-7</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Celiac Disease (CD) is present in 1-16.4% of patients with type 1 diabetes mellitus. The most important serological markers of CD are anti-endomysial (EMA), anti-tissue transglutaminase (tTGA) and antigliadin antibodies (AGA).</AbstractText>
      <AbstractText Label="AIM/HYPOTHESIS" NlmCategory="OBJECTIVE">The objective of this work is to determine the frequency of tTGA and/or AGA in latent autoimmune diabetes of adult (LADA) and subjects with type 2 diabetes (T2DM), as well as to evaluate their relation with several clinical and biochemical characteristics.</AbstractText>
      <AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">Forty three subjects with LADA and 99 with T2DM were studied. The presence of AGA, tTGA was determined in the sera of these patients. The variables: sex, age, duration of diabetes, treatment, body mass index (BMI) and fasting blood glucose concentration were also recorded.</AbstractText>
      <AbstractText Label="RESULTS" NlmCategory="RESULTS">No differences were found in the frequency of celiac disease associated antibodies between LADA and T2DM subjects. The presence of celiac disease related antibodies was more frequent in patients with a normal or low BMI.</AbstractText>
      <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Celiac disease does not seem to be related with pancreatic autoimmunity in type 2 diabetes. Celiac disease causes a decrease of body mass index in type 2 diabetes while pancreatic islet autoimmunity in this entity masks this effect.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Sánchez</LastName>
        <ForeName>J C</ForeName>
        <Initials>JC</Initials>
        <AffiliationInfo>
          <Affiliation>Department of Diabetes Mellitus Immunity, National Institute of Endocrinology, Zapata and D, Vedado, Havana 10 400, Cuba.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="N">
        <LastName>Cruz</LastName>
        <ForeName>Julio Cesar Sánchez</ForeName>
        <Initials>JC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Cabrera-Rode</LastName>
        <ForeName>E</ForeName>
        <Initials>E</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Rode</LastName>
        <ForeName>Eduardo Cabrera</ForeName>
        <Initials>EC</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Sorell</LastName>
        <ForeName>L</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Gómez</LastName>
        <ForeName>Luis Sorell</ForeName>
        <Initials>LS</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Galvan</LastName>
        <ForeName>J A</ForeName>
        <Initials>JA</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Cabrera</LastName>
        <ForeName>José A Galvan</ForeName>
        <Initials>JA</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Hernandez</LastName>
        <ForeName>A</ForeName>
        <Initials>A</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Ortega</LastName>
        <ForeName>Ania Hernandez</ForeName>
        <Initials>AH</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Molina</LastName>
        <ForeName>G</ForeName>
        <Initials>G</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Mato</LastName>
        <ForeName>Gisela Molina</ForeName>
        <Initials>GM</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Perich</LastName>
        <ForeName>P A</ForeName>
        <Initials>PA</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Amador</LastName>
        <ForeName>Pedro A Perich</ForeName>
        <Initials>PA</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Licea</LastName>
        <ForeName>M E</ForeName>
        <Initials>ME</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Puig</LastName>
        <ForeName>Manuel E Licea</ForeName>
        <Initials>ME</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Domínguez</LastName>
        <ForeName>E</ForeName>
        <Initials>E</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Alonso</LastName>
        <ForeName>Emma Domínguez</ForeName>
        <Initials>ED</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Díaz-Horta</LastName>
        <ForeName>O</ForeName>
        <Initials>O</Initials>
      </Author>
      <Author ValidYN="N">
        <LastName>Díaz-Horta</LastName>
        <ForeName>Oscar</ForeName>
        <Initials>O</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>9007-90-3</RegistryNumber>
      <NameOfSubstance UI="D005903">Gliadin</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>EC 2.3.2.13</RegistryNumber>
      <NameOfSubstance UI="D011503">Transglutaminases</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <CommentsCorrectionsList>
    <CommentsCorrections RefType="ErratumIn">
      <RefSource>Autoimmunity. 2007 May;40(3):234-5</RefSource>
      <Note>Cruz, Julio Cesar Sánchez [corrected to Sánchez, J C]; Rode, Eduardo Cabrera [corrected to Cabrera-Rode, E]; Gómez, Luis Sorell [corrected to Sorell, L]; Cabrera, José A Galvan [corrected to Galvan, J A]; Ortega, Ania Hernandez [corrected to Hernandez,</Note>
    </CommentsCorrections>
  </CommentsCorrectionsList>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002446" MajorTopicYN="N">Celiac Disease</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005903" MajorTopicYN="N">Gliadin</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D011503" MajorTopicYN="N">Transglutaminases</DescriptorName>
      <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364501</ArticleId>
    <ArticleId IdType="pii">773217245</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601118825</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364502</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>18</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2010</Year>
    <Month>11</Month>
    <Day>18</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>2</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Changes in expression of P2X7 receptors in NOD mouse pancreas during the development of diabetes.</ArticleTitle>
    <Pagination>
      <MedlinePgn>108-16</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText>This study examined the expression of P2X7 receptors in pancreatic islets of the non-obese diabetic (NOD) mouse model of human autoimmune insulin-dependent diabetes mellitus, to determine whether they are involved in islet cell destruction during early- and late-developing diabetes. Pancreatic cells containing glucagon (alpha-cells), insulin (beta-cells) and somatostatin (delta-cells) were co-localized with P2X7 receptors. We examined P2X7 receptor expression in normal and diabetic spleens using flow cytometry. In non-diabetic NOD controls, P2X7 receptors were expressed in glucagon-containing cells at the periphery of islets, being consistent with previous studies. In early NOD diabetes (12 weeks), there was migration of peripheral P2X7 receptor positive, glucagon-containing cells into the center of islets. In late NOD diabetes (34 weeks), P2X7 receptor- and glucagon-stained alpha-cells were gone from islets. Migration of macrophages and dendritic cells into islets took place, but they lacked P2X7 immunoreactivity. There was no significant difference in the percentage of splenic macrophages stained for P2X7 receptors from control and diabetic spleens. In conclusion, in the development of early to late diabetes, there is a down-regulation of P2X7 receptors on islet cells and a loss of alpha- and beta-cell populations. P2X7 receptor signalling might be involved in alpha-cell clearance from late diabetic islets.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Coutinho-Silva</LastName>
        <ForeName>Robson</ForeName>
        <Initials>R</Initials>
        <AffiliationInfo>
          <Affiliation>Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London, UK.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Robson</LastName>
        <ForeName>Tim</ForeName>
        <Initials>T</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Beales</LastName>
        <ForeName>Philip E</ForeName>
        <Initials>PE</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Burnstock</LastName>
        <ForeName>Geoffrey</ForeName>
        <Initials>G</Initials>
      </Author>
    </AuthorList>
    <Language>eng</Language>
    <GrantList CompleteYN="Y">
      <Grant>
        <GrantID>062754/Z00Z</GrantID>
        <Agency>Wellcome Trust</Agency>
        <Country>United Kingdom</Country>
      </Grant>
    </GrantList>
    <PublicationTypeList>
      <PublicationType UI="D016428">Journal Article</PublicationType>
      <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
    </PublicationTypeList>
  </Article>
  <MedlineJournalInfo>
    <Country>England</Country>
    <MedlineTA>Autoimmunity</MedlineTA>
    <NlmUniqueID>8900070</NlmUniqueID>
    <ISSNLinking>0891-6934</ISSNLinking>
  </MedlineJournalInfo>
  <ChemicalList>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C546468">P2RX7 protein, human</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="C546469">P2rx7 protein, mouse</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D018048">Receptors, Purinergic P2</NameOfSubstance>
    </Chemical>
    <Chemical>
      <RegistryNumber>0</RegistryNumber>
      <NameOfSubstance UI="D058486">Receptors, Purinergic P2X7</NameOfSubstance>
    </Chemical>
  </ChemicalList>
  <CitationSubset>IM</CitationSubset>
  <MeshHeadingList>
    <MeshHeading>
      <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D050416" MajorTopicYN="N">Glucagon-Secreting Cells</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D050417" MajorTopicYN="N">Insulin-Secreting Cells</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D007515" MajorTopicYN="N">Islets of Langerhans</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
      <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D018048" MajorTopicYN="N">Receptors, Purinergic P2</DescriptorName>
      <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D058486" MajorTopicYN="N">Receptors, Purinergic P2X7</DescriptorName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D019864" MajorTopicYN="N">Somatostatin-Secreting Cells</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
    <MeshHeading>
      <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
      <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
    </MeshHeading>
  </MeshHeadingList>
</MedlineCitation>
<PubmedData>
  <History>
    <PubMedPubDate PubStatus="pubmed">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="medline">
      <Year>2007</Year>
      <Month>6</Month>
      <Day>19</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
    <PubMedPubDate PubStatus="entrez">
      <Year>2007</Year>
      <Month>3</Month>
      <Day>17</Day>
      <Hour>9</Hour>
      <Minute>0</Minute>
    </PubMedPubDate>
  </History>
  <PublicationStatus>ppublish</PublicationStatus>
  <ArticleIdList>
    <ArticleId IdType="pubmed">17364502</ArticleId>
    <ArticleId IdType="pii">773217130</ArticleId>
    <ArticleId IdType="doi">10.1080/08916930601118841</ArticleId>
  </ArticleIdList>
</PubmedData>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
  <PMID Version="1">17364503</PMID>
  <DateCompleted>
    <Year>2007</Year>
    <Month>06</Month>
    <Day>18</Day>
  </DateCompleted>
  <DateRevised>
    <Year>2008</Year>
    <Month>11</Month>
    <Day>21</Day>
  </DateRevised>
  <Article PubModel="Print">
    <Journal>
      <ISSN IssnType="Print">0891-6934</ISSN>
      <JournalIssue CitedMedium="Print">
        <Volume>40</Volume>
        <Issue>2</Issue>
        <PubDate>
          <Year>2007</Year>
          <Month>Mar</Month>
        </PubDate>
      </JournalIssue>
      <Title>Autoimmunity</Title>
      <ISOAbbreviation>Autoimmunity</ISOAbbreviation>
    </Journal>
    <ArticleTitle>Two-year follow-up of anti-transglutaminase autoantibodies among celiac children on gluten-free diet: comparison of IgG and IgA.</ArticleTitle>
    <Pagination>
      <MedlinePgn>117-21</MedlinePgn>
    </Pagination>
    <Abstract>
      <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the evolution of IgA and IgG autoantibodies against tissue transglutaminase (tTGase) in celiac patients on gluten-free diet (GFD).</AbstractText>
      <AbstractText Label="METHODS" NlmCategory="METHODS">IgA and IgG anti-tTGAse autoantibodies was evaluated in 93 patients (58 girls and 35 boys; mean age 3.56 +/- 3.04 years; range 0.94-17.5 years) at diagnosis of celiac disease and after 1, 2, 4, 6, 12, 18, 24 months of follow-up on GFD. Autoantibodies were measured with a radioassay using in vitro transcribed-translated human recombinant tTGAse, and immune complexes were precipitated with protein A- or anti-IgA-agarose for IgG and IgA, respectively.</AbstractText>
      <AbstractText Label="RESULTS" NlmCategory="RESULTS">Autoantibody titers started to decline very soon after removal of gluten, and no significant differences in the decrease rate between IgG and IgA antibodies were observed. After 6 months on GFD, 63 and 49% of the patients were negative for IgG and IgA, respectively. Patients who remained autoantibody-positive after 6 months of treatment initially presented with significantly higher titers at the time of diagnosis compared to patients that had lost their antibodies by that time. Children diagnosed before the age of two years presented lower autoantibody titers, while patients positive for HLA-DR7 had higher anti-tTGase levels, especially IgA.</AbstractText>
      <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There are no differences in the performance of IgG and IgA class autoantibodies in the evolution of celiac patients. Between 3 and 6 months on GFD, almost half of the patients are negative for anti-tTGase antibodies. In our experience, they can be of help in evaluating compliance with diet, at least during the first two years of treatment.</AbstractText>
    </Abstract>
    <AuthorList CompleteYN="Y">
      <Author ValidYN="Y">
        <LastName>Martín-Pagola</LastName>
        <ForeName>Ainhoa</ForeName>
        <Initials>A</Initials>
        <AffiliationInfo>
          <Affiliation>Endocrinology and Diabetes Research Group, Hospital de Cruces, Plaza de Cruces s/n, Barakaldo 48903, Bizcaia, Spain.</Affiliation>
        </AffiliationInfo>
      </Author>
      <Author ValidYN="Y">
        <LastName>Ortiz-Paranza</LastName>
        <ForeName>Lourdes</ForeName>
        <Initials>L</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Bilbao</LastName>
        <ForeName>Jose Ramon</ForeName>
        <Initials>JR</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>de Nanclares</LastName>
        <ForeName>Guiomar Pérez</ForeName>
        <Initials>GP</Initials>
      </Author>
      <Author ValidYN="Y">
        <LastName>Estevez</LastName>
        <ForeName>Elena Perez</ForeName>
